

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 November 2007 (29.11.2007)

PCT

(10) International Publication Number
WO 2007/137037 A1

- (51) International Patent Classification:
A61N 1/365 (2006.01)
- (21) International Application Number:
PCT/US2007/068954
- (22) International Filing Date: 15 May 2007 (15.05.2007)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
11/383,933 17 May 2006 (17.05.2006) US
11/383,926 17 May 2006 (17.05.2006) US
- (71) Applicant (for all designated States except US): **CARDIAC PACEMAKERS, INC.** [US/US]; 4100 Hamline Avenue North, St. Paul, MN 55112 (US).
- (71) Applicant and
- (72) Inventor: **KWOK, Jonathan, T.** [CA/US]; 4854 Churchill Street, Shoreview, MN 55126 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KANE, Michael, John** [US/US]; 5173 Marquess Trail, Lake Elmo, MN 55042 (US). **VON ARX, Jeffrey, Allen** [US/US]; 2115 Emerson Ave. S., Minneapolis, MN 55405 (US). **BENTSEN, James, Gregory** [US/US]; 2818 First St. N., North St. Paul, MN 55109 (US).


- (74) Agent: **DEFFNER, Mark, E.**; Pauly, DeVries Smith & Deffner, L.L.C., Plaza VII, Suite 3000, 45 South Seventh Street, Minneapolis, MN 55402-1630 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMPLANTABLE MEDICAL DEVICE WITH CHEMICAL SENSOR AND RELATED METHODS



(57) Abstract: In an embodiment, the invention includes an implantable medical device with a pulse generator and a chemical sensor in communication with the pulse generator, the chemical sensor configured to detect an ion concentration in a bodily fluid. In an embodiment, the invention includes a method for providing cardiac arrhythmia therapy to a patient including sensing a physiological concentration of an analyte, communicating data regarding the physiological concentration of the analyte to an implanted pulse generator, and delivering therapy to the patient based in part on the physiological concentration of the ion. In an embodiment, the invention includes a method for monitoring diuretic therapy. In an embodiment, the invention includes a method for controlling delivery of an active agent into a human body. Other aspects and embodiments are provided herein.

WO 2007/137037 A1

IMPLANTABLE MEDICAL DEVICE WITH CHEMICAL SENSOR AND RELATED METHODS

This application is being filed as a PCT International Patent application
5 on 15 May 2007, in the name of Cardiac Pacemakers, Inc., a U.S. national
corporation, applicant for the designation of all countries except the US, and
Michael J. Kane, a U.S. citizen, Jeffrey A. Von Arx, a U.S. citizen, James G.
Bentsen, a U.S. citizen, and Jonathan T. Kwok, a Canadian citizen, applicants
for the designation of the US only, and claims priority to U.S. Patent Application
10 Serial Number 11/383,933, titled IMPLANTABLE MEDICAL DEVICE WITH
CHEMICAL SENSOR AND RELATED METHODS, filed 17 May 2006; and
U.S. Patent Application Serial Number 11/383,926, titled "IMPLANTABLE
MEDICAL DEVICE WITH CHEMICAL SENSOR AND RELATED
METHODS", filed 17 May 2006; the contents of both of which are herein
15 incorporated by reference.

TECHNICAL FIELD

This disclosure relates generally to implantable medical devices and,
more particularly, to implantable medical devices with a chemical sensor and
20 related methods.

BACKGROUND OF THE INVENTION

Implantable medical devices (IMDs), such as cardiac rhythm
management systems, are commonly used to provide treatment or therapy to
25 patients. Cardiac rhythm management systems can include pacemakers.
Pacemakers deliver timed sequences of low energy electrical stimuli, called
pacing pulses, to the heart, via an intravascular lead wire or catheter (referred to
as a "lead") having one or more electrodes disposed in or about the heart. Heart
contractions are initiated in response to such pacing pulses. Pacemakers are
30 often used to treat patients with bradyarrhythmias, that is, hearts that beat too
slowly, or irregularly. Such pacemakers may also coordinate atrial and
ventricular contractions to improve pumping efficiency.

Cardiac rhythm management systems can also include cardiac

resynchronization therapy (CRT) devices for coordinating the spatial nature of heart depolarizations for improving pumping efficiency. For example, a CRT device may deliver appropriately timed pacing pulses to different locations of the same heart chamber to better coordinate the contraction of that heart chamber, or the CRT device may deliver appropriately timed pacing pulses to different heart chambers to improve the manner in which these different heart chambers contract together.

Cardiac rhythm management systems also include defibrillators that are capable of delivering higher energy electrical stimuli to the heart. Such defibrillators include cardioverters, which synchronize the delivery of such stimuli to sensed intrinsic heart activity signals. Defibrillators are often used to treat patients with tachyarrhythmias, that is, hearts that beat too quickly. A defibrillator is capable of delivering a high energy electrical stimulus that is sometimes referred to as a defibrillation countershock, also referred to simply as a "shock." The countershock interrupts the tachyarrhythmia, allowing the heart to reestablish a normal rhythm for the efficient pumping of blood. In addition to pacers, CRT devices, and defibrillators, cardiac rhythm management systems can also include devices that combine these functions, as well as monitors, drug delivery devices, and other implantable or external systems or devices for diagnosing or treating the heart.

Certain physiological analytes impact many of the problems that implantable medical devices are designed to treat. As one example, potassium ion concentrations can affect a patient's cardiac rhythm. Therefore, medical professionals frequently evaluate physiological potassium ion concentration when diagnosing a cardiac rhythm problem. However, measuring physiological concentrations of analytes, such as potassium, generally requires drawing blood from the patient. Blood draws are commonly done at a medical clinic or hospital and therefore generally require the patient to physically visit a medical facility. As a result, despite their significance, physiological analyte concentrations are frequently measured only sporadically.

SUMMARY OF THE INVENTION

Disclosed herein, among other things, is an implantable medical device (IMD) for sensing chemical concentration in a bodily fluid. In an embodiment, the invention includes an implantable medical device with a pulse generator and a chemical sensor in communication with the pulse generator, the chemical
5 sensor configured to detect an ion concentration in a bodily fluid. The chemical sensor can include a sensing element, an optical excitation assembly, and an optical detection assembly.

In an embodiment, the invention includes an implantable cardiac rhythm management system having a pulse generator and a chemical sensor in
10 communication with the pulse generator, the chemical sensor configured to detect an ion concentration in a bodily fluid. The chemical sensor can include a sensing element, an optical excitation assembly, and an optical detection assembly.

In an embodiment, the invention includes a method for providing cardiac arrhythmia therapy to a patient. The method can include optically measuring a
15 physiological concentration of an ion in a bodily fluid of the patient with an implanted chemical sensor. The method can further include transmitting data regarding the physiological concentration of the ion to an implanted pulse generator. The method can also include delivering therapy from the implanted
20 pulse generator to the patient based in part on the physiological concentration of the ion.

In an embodiment, the invention includes a method of monitoring diuretic therapy. The method can include optically sensing a physiological
25 concentration of an ion in a bodily fluid of the patient with an implanted chemical sensor. The method can also include communicating data regarding the physiological concentration of the ion to an implanted pulse generator. The method can further include altering the delivery of the diuretic therapy to the patient based in part on the physiological concentration of the ion.

In an embodiment, the invention includes a method for controlling
30 delivery of an active agent into a human body. The method can include measuring a physiological concentration of one or more analytes with an implanted system comprising a pulse generator and a chemical sensor, the

chemical sensor comprising a sensing element, an excitation assembly, and a detection assembly. The method can further include varying delivery of the substance at least in part as a function of the measured concentration of the one or more analytes.

5 This summary is an overview of some of the teachings of the present application and is not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details are found in the detailed description and appended claims. Other aspects will be apparent to persons skilled in the art upon reading and understanding the following detailed description and viewing
10 the drawings that form a part thereof, each of which is not to be taken in a limiting sense. The scope of the present invention is defined by the appended claims and their legal equivalents.

BRIEF DESCRIPTION OF THE DRAWINGS

15 FIG. 1 schematically illustrates aspects of an implantable medical device (IMD) with a chemical sensor in accordance with an embodiment of the invention.

 FIG. 2 schematically illustrates an IMD with a chemical sensor in accordance with another embodiment of the invention.

20 FIG. 3 schematically illustrates an IMD with a chemical sensor in accordance with another embodiment of the invention.

 FIG. 4 schematically illustrates an IMD with a chemical sensor in accordance with another embodiment of the invention.

 FIG. 5 schematically illustrates an IMD with a chemical sensor in
25 accordance with another embodiment of the invention.

 FIG. 6 illustrates an implantable medical device (IMD) with a chemical sensor in the header, according to various embodiments.

 FIG. 7 illustrates an implantable medical device (IMD) with a chemical
30 sensor integrated with the body of the device, according to various embodiments.

 FIG. 8 is a cross-sectional view of a sensing element, according to various embodiments.

FIG. 9 is a cross-sectional view of a sensing element, according to another embodiment of the invention.

FIG. 10 is a cross-sectional view of a sensing element, according to another embodiment of the invention.

5 FIG. 11 schematically illustrates an embodiment of a device for measuring a physiological analyte concentration.

FIG. 12 schematically illustrates a duty cycling scheme for operation of an optical sensor in accordance with an embodiment of the invention.

10

DETAILED DESCRIPTION OF THE INVENTION

The disclosures of commonly-owned U.S. Patent Application Nos. 10/677,144, filed on September 30, 2003, and 10/334,283, filed on January 2, 2003, are herein incorporated by reference.

15 Physiological analyte concentrations are important data points for both the diagnosis and treatment of many medical problems. For example, knowledge of potassium ion concentrations can be important to the correct diagnosis of cardiac arrhythmias. The excitation cycle of cardiac cells is influenced by their resting electrical potential, and by the activity of ion
20 channels (such as potassium, sodium, and calcium) in the cell membrane of the cardiac cells. By way of example, potassium ion channels play an important role in returning a cardiac cell to a resting electrical potential following an action potential. When the concentration of potassium in the plasma is within a normal physiological range, the potassium ion channels can function effectively.
25 Unfortunately, when the potassium concentration in the plasma is elevated (“hyperkalemia”) the concentration gradient of potassium across the cardiac cell membrane is reduced and the cardiac cell generally becomes depolarized and inexcitable. In contrast, when the potassium concentration is low (“hypokalemia”), the concentration gradient of potassium across the cardiac cell
30 membrane is increased resulting in hyperpolarization of the resting electrical potential. Hypokalemia can lead to arrhythmias, such as atrial fibrillation. Thus, knowledge of potassium ion concentrations can be valuable in forming a

correct diagnosis of a cardiac rhythm problem. Likewise, the concentrations of other physiological ions, such as sodium and calcium, can also be important in the diagnosis and treatment of cardiac arrhythmias.

5 Beyond cardiac rhythm problems, ion sensing can also be useful in the context of monitoring drug therapy, monitoring renal function, titrating drugs (such as heart failure medications), monitoring for heart failure decompensation, and observing primary electrolyte imbalance subsequent to dietary intake or renal excretion variations.

Embodiments of the present invention can be used to gather
10 concentration data regarding medically relevant analytes in bodily fluids. Specifically, embodiments of the present invention can include an implantable medical device including a pulse generator to deliver electrical pulses and/or shock therapy and a chemical sensor in communication with the pulse generator.

The chemical sensor can be configured to detect an ion concentration in a
15 bodily fluid, and can include a sensing element, an excitation assembly, and a detection assembly configured to receive light from the sensing element.

Integrating the functionality of chemical sensors with implantable cardiac rhythm management devices can offer therapeutic advantages. The data generated by an implantable cardiac rhythm device and the data generated by a
20 chemical sensor offer mutually orthogonal but linked views of the physiologic state of the patient. Combining these views can provide a health professional with additional insight into the patient's health. As just one example, an erratic heart-rate in the presence of very high or very low potassium concentrations indicates a greater level of risk to the patient than either condition presented
25 separately. Various embodiments of the present invention can detect both analyte concentrations, such as potassium concentration, and cardiac arrhythmias so that risks can be quickly identified and, in some embodiments, conveyed to a health professional when appropriate.

Continuous or near-continuous monitoring of physiological analytes can
30 offer therapeutic benefits. Typically, the process for measuring physiological concentrations of analytes involves drawing blood from the patient. Blood draws are typically done at a medical clinic or hospital. Therefore, the patient

must generally visit a medical facility, and as a result, physiological analyte concentrations are generally measured only sporadically. Accordingly, the clinician is usually presented with only sporadic snapshot data representing a patient's condition only on particular days. While this snapshot data is valuable, 5 having data stretching over a longer continuous period of time can be of greater value because it can more accurately reflect trends as well as periodic fluctuations that could be caused by diet, activity, medications, etc. Various embodiments of the invention, including an implantable medical device with a chemical sensor, can be used to provide clinicians with continuous or semi- 10 continuous data regarding analyte concentrations.

When a medical device is implanted within a host, the immune system of the host senses the presence of the foreign body and starts what is referred to as a foreign body response. Within hours, there is adherence and activation of platelets in the area of the inserted device, followed by the release of growth 15 factors and chemotactic agents from platelet granules. Granulocytes and mononuclear phagocytes then migrate into the area. Subsequently, the site is infiltrated by fibroblasts. Within the first few weeks, the fibroblasts multiply and lay down collagen that begins to form an avascular connective tissue envelope or "pocket". This process can continue for months and generally 20 results in the complete encasement of the medical device in an avascular pocket with walls that are 50 μm to 200 μm thick.

Unfortunately, chronically implanted medical devices with chemical sensors can suffer from problems as a result of the foreign body response. The pocket wall itself is poorly vascularized and serves to prevent the medical device 25 from interfacing with highly vascularized tissues. Without interfacing with highly vascularized tissues, the medical device may not be able to accurately detect physiological conditions outside of the pocket. As an example, glucose is known to traverse the pocket wall relatively poorly and therefore glucose levels within the pocket do not accurately reflect physiological glucose levels outside 30 of the pocket. Therefore most implanted glucose sensors become increasingly inaccurate as the avascular pocket forms around them. However, as detailed in Example 1 below, the Applicants have discovered that ions, such as sodium and

potassium ions, behave differently than glucose in traversing the pocket wall. Specifically, Example 1 shows that ions such as sodium and potassium are able to traverse the pocket wall sufficiently well to enable accurate measurements regarding their physiological concentrations to be taken from within the pocket wall. Therefore, chemical sensors that detect physiological ions, such as sodium and potassium, can be integrated with chronically implanted medical devices, such as implantable cardiac rhythm management devices.

Closely related to the issues associated with the foreign body response are issues associated with biofouling of implanted medical devices. Biofouling can include the accumulation of biomolecules such as proteins, fats, and/or carbohydrates on the surfaces of an implanted device. While not intending to be bound by theory, biofouling is believed to lead to drift and loss of responsiveness in the context of electrochemical (such as potentiometric) chemical sensors that are implanted chronically. For ion selective electrodes, the measured electromotive force primarily depends on the potential change across the interface of the sample and membrane phases. This interfacial measured electromotive force can become compromised by the deposition of proteins and other biomolecules on the sensor surface. Furthermore, in ion-selective electrodes, the bulk of the sensor membrane is generally impregnated with a known excess of an analyte. The Nernstian response is only observed if the organic phase boundary concentration is not significantly altered as a function of the sample concentration. For acute measurements, this condition is maintained. However, for chronic monitoring, preloaded analyte can leach from the sensor film, compromising calibration.

In contrast, both non-carrier and carrier based optical sensing elements rely on concentration changes within the bulk of the sensing element. Therefore, optical sensing approaches are believed to be generally less susceptible to biofouling problems than electrochemical chemical sensors relying on interfacial phenomena.

It will be appreciated that the sensing of analyte concentrations can be directed at a specific analyte or a plurality of different analytes. In an embodiment, the analyte sensed is one or more analytes relevant to cardiac

health. In an embodiment, the analyte sensed is one or more analytes indicative of renal health. The analyte sensed can be an ion or a non-ion. The analyte sensed can be a cation or an anion. Specific examples of analytes that can be sensed include acetic acid (acetate), aconitic acid (aconitate), ammonium, blood urea nitrogen (BUN), B-type natriuretic peptide (BNP), bromate, calcium, carbon dioxide, cardiac specific troponin, chloride, choline, citric acid (citrate), cortisol, copper, creatinine, creatinine kinase, fluoride, formic acid (formate), glucose, hydronium ion, isocitrate, lactic acid (lactate), lithium, magnesium, maleic acid (maleate), malonic acid (malonate), myoglobin, nitrate, nitric-oxide, oxalic acid (oxalate), oxygen, phosphate, phthalate, potassium, pyruvic acid (pyruvate), selenite, sodium, sulfate, urea, uric acid, and zinc. Inorganic cations sensed by this method include but not limited to hydronium ion, lithium ion, sodium ion, potassium ion, magnesium ion, calcium ion, silver ion, zinc ion, mercury ion, lead ion and ammonium ion. Inorganic anions sensed by this method include but not limited to carbonate anion, nitrate anion, sulfite anion, chloride anion and iodide anion. Organic cations sensed by this method include but are not limited to norephedrine, ephedrine, amphetamine, procaine, prilocaine, lidocaine, bupivacaine, lignocaine, creatinine and protamine. Organic anions sensed by this method include but not limited to salicylate, phthalate, maleate, and heparin. Neutral analytes sensed by this method include but not limited to ammonia, ethanol, and organic amines. In an embodiment, ions that can be sensed include potassium, sodium, chloride, calcium, and hydronium (pH). In a particular embodiment, concentrations of both sodium and potassium are measured. In another embodiment, concentrations of both magnesium and potassium are measured.

In some embodiments, the physiological concentration of an analyte is sensed directly. In other embodiments, the physiological concentration of an analyte is sensed indirectly. By way of example, a metabolite of a particular analyte can be sensed instead of the particular analyte itself. In other embodiments, an analyte can be chemically converted into another form in order to make the process of detection easier. By way of example, an enzyme can be used to convert an analyte into another compound which is easier to detect. For

example, the hydrolysis of creatinine into ammonia and N-methylhydantoin can be catalyzed by creatinine deiminase and the resulting ammonia can be detected by a chemical sensor. As another example, the oxidation of glucose into gluconolactone and hydrogen peroxide can be catalyzed by glucose oxidase and the resulting hydrogen peroxide can be detected by a chemical sensor. In some embodiments, the enzyme is immobilized to prevent it from leaching out of the chemical sensor.

Referring now to FIG. 1, a schematic view of an implantable medical device (IMD) 102 with a chemical sensor 104 is shown. In various embodiments, the IMD 102 can include a cardiac rhythm management device, such as a pacemaker, a cardiac resynchronization therapy (CRT) device, a remodeling control therapy (RCT) device, a cardioverter/defibrillator, or a pacemaker-cardioverter/defibrillator. One exemplary cardiac rhythm management device is disclosed in commonly assigned USPN 6,928,325, issued 8/9/2005, the contents of which is herein incorporated by reference. In the embodiment shown in FIG. 1, the chemical sensor 104 is integrated with the IMD 102. The chemical sensor 104 is configured to detect a concentration of an analyte, such as an ion, in a bodily fluid. Bodily fluids can include blood, interstitial fluid, serum, lymph, and serous fluid. The chemical sensor 104 includes a sensing element 108. The chemical sensor 104 also includes an excitation assembly 106 and a detection assembly 110. The chemical sensor 104 can be configured to operate in various ways including colorimetrically and/or fluorimetrically.

It will be appreciated that chemical sensors can be configured to operate in various other ways. For example, optical chemical sensors can be configured to directly illuminate tissues or fluids of the body and then analyze the resulting spectral response to determine analyte concentrations (e.g., a direct spectroscopic approach). However, while not intending to be bound by theory, it is believed that such direct spectroscopic approaches generally suffer from issues that can impair accuracy including background interference and/or temporal signal drift associated with biofouling.

The excitation assembly 106 can be configured to illuminate the sensing element 108. In an embodiment, the excitation assembly 106 includes a light-emitting diode (LED). In some embodiments, the excitation assembly includes solid state light sources such as GaAs, GaAlAs, GaAlAsP, GaAlP, GaAsP, GaP, 5 GaN, InGaAlP, InGaN, ZnSe, or SiC light emitting diodes or laser diodes that excite the sensing element(s) at or near the wavelength of maximum absorption for a time sufficient to emit a return signal. In other embodiments, the excitation assembly can include other light emitting components including incandescent components. In some embodiments, the excitation assembly 106 can include a 10 waveguide. The excitation assembly 106 can also include one or more bandpass filters and/or focusing optics.

In some embodiments, the excitation assembly includes a plurality of LEDs with bandpass filters, each of the LED-filter combinations emitting at a different center frequency. According to various embodiments, the LEDs 15 operate at different center-frequencies, sequentially turning on and off during a measurement, illuminating the sensing element. As multiple different center-frequency measurements are made sequentially, a single unfiltered detector can be used.

The sensing element 108 can include one or more ion selective sensors. 20 Physiological analytes of interest can diffuse into the sensing element 108 and bind with an ion selective sensor to result in a fluorimetric or colorimetric response. Exemplary ion selective sensors are described more fully below.

The detection assembly 110 can be configured to receive light from the sensing element 108. In an embodiment, the detection assembly 110 includes a 25 component to receive light. By way of example, in some embodiments, the detection assembly 110 includes a charge-coupled device (CCD). In other embodiments, the detection assembly can include a photodiode, a junction field effect transistor (JFET) type optical sensor, or a complementary metal-oxide semiconductor (CMOS) type optical sensor. In an embodiment, the detection 30 assembly 110 includes an array of optical sensing components. In some embodiments, the detection assembly 110 can include a waveguide. The detection assembly 110 can also include one or more bandpass filters and/or

focusing optics. In an embodiment, the detection assembly 110 includes one or more photodiode detectors, each with an optical bandpass filter tuned to a specific wavelength range.

The excitation and detection assemblies can be integrated using
5 bifurcated fiber-optics that direct excitation light from a light source to one or more sensing elements, or simultaneously to sensing elements and a reference channel. Return fibers can direct emission signals from the sensing element(s) and reference channels to one or more optical detectors for analysis by a processor. In another embodiment, the excitation and detection assemblies are
10 integrated using a beam-splitter assembly and focusing optical lenses that direct excitation light from a light source to the sensing element and direct emitted or reflected light from the sensing element to an optical detector for analysis by a processor.

In some embodiments, the detection assembly 110 is disposed on the
15 same side of the sensing element 108 as the excitation assembly 106. In other embodiments, the detection assembly 110 is on the opposite side of the sensing element 108 from the excitation assembly 106. It will be appreciated that many different physical arrangements of the components are possible.

Embodiments of the invention can include an implantable medical device
20 having a chemical sensor co-located with a pulse generator body, located on a lead connected to a pulse generator body through a header, or separately located in a sensor module in wired or wireless communication with a pulse generator body.

FIG. 2 schematically illustrates an implantable system 200 having a pulse
25 generator 202 co-located with an integrated chemical sensor 203, according to various embodiments. The term "pulse generator" as used herein shall refer to the part or parts of an implanted system, such as a cardiac rhythm management system or a neurological therapy system, containing the power source and circuitry for delivering pacing and/or shock therapy. The pulse generator 202
30 can include a controller circuit 210 (including components such as a pulse generator circuit) to communicate with the chemical sensor 203, a telemetry circuit 212 to communicate with the controller circuit 210 and an external

module 220 (such as a programmer module), and a memory circuit 214 to communicate with the controller circuit 210. The chemical sensor 203 includes a sensing element 204, an optical excitation assembly 206, and an optical detection assembly 208. The implantable system 200 can include at least one
5 implantable lead 222 coupled to the pulse generator 202 via the controller circuit 210 (or pulse generator circuit), the at least one implantable lead 222 configured to be connected to at least one implantable electrode 224 capable of electrically stimulating tissue. However, it will be appreciated that embodiments of the invention can also include implantable systems, such as cardiac rhythm
10 management systems, that do not include pacing leads, such as leadless implantable cardioverter-defibrillators.

In various embodiments, the controller circuit, telemetry circuit, and memory circuit are within a device body or housing. In some embodiments, the chemical sensor 203, or some of the components thereof, are disposed within the
15 device body or housing. In some embodiments, the chemical sensor 203, or some of the components thereof are disposed on the device body or in an aperture in the device body. In an alternative embodiment, the optical excitation assembly 206 and the optical detection assembly 208 can be disposed within the device body, while the sensing element 204 is disposed outside of the device
20 body. In such an embodiment, optical communication between the optical excitation assembly 206, the sensing element 204, and the optical detection assembly 208 is maintained by waveguides, optical lenses, or optical windows. For example, an optical lens or an optical window (transparent member) can be disposed within an aperture on the device body, the sensing element can be
25 optically coupled to the outside of the lens or window, and the optical excitation assembly and optical detection assembly can be optically coupled to the inside of the lens or window.

FIG. 3 illustrates an embodiment of an implantable system 300 having a pulse generator 302 coupled to (such as electrically or optically), but separate
30 from, a chemical sensor 303. The pulse generator 302 can include a controller circuit 310 to communicate with the chemical sensor 303, a telemetry circuit 312 to communicate with the controller circuit 310 and an external module 320 (such

as a programmer module), and a memory circuit 314 to communicate with the controller circuit 310. The chemical sensor 303 includes a sensing element 304, an optical excitation assembly 306, and an optical detection assembly 308. The implantable system 300 can include at least one implantable lead 322 connected to the pulse generator 302, the at least one implantable lead 322 configured to be connected to at least one implantable electrode 324 capable of electrically stimulating tissue. The implantable system 300, can include a chemical sensing lead to electrically or optically couple the pulse generator 302 with the chemical sensor 303.

10 FIG. 4 illustrates an embodiment of an implantable system 400 having a pulse generator 402 in wireless communication with a chemical sensor 403. The pulse generator 402 can include a controller circuit 410, a telemetry circuit 412 to communicate with the controller circuit 410, the chemical sensor 403, and an external module 420 (such as a programmer module), and a memory circuit 414 to communicate with the controller circuit 410. The chemical sensor 403 includes a sensing element 404, an optical excitation assembly 406, and an optical detection assembly 408. The implantable system 400 can include at least one implantable lead 422 connected to the pulse generator 402, the at least one implantable lead 422 configured to be connected to at least one implantable electrode 424 capable of electrically stimulating tissue. In this embodiment, the pulse generator 402 is in wireless communication with the chemical sensor 403. It will be appreciated that wireless communication can be achieved through various approaches including radio frequency links, ultrasonic links, acoustic links, and the like. In some embodiments, the chemical sensor 403 can be in a self-contained device with its own internal power supply and radio frequency or acoustic communication capability (having a radio frequency communication link, an ultrasonic communication link, and/or an acoustic communication link).

25 FIG. 5 illustrates an embodiment including a system 500 having a pulse generator 502 and a chemical sensor 503 integrated with a lead 522. The lead 522 is coupled to the pulse generator 502. The chemical sensor 503 can be coupled to the lead 522 at any point between the proximal and distal ends of the lead 522. In an embodiment, the chemical sensor 503 is coupled to the distal

end of the lead 522. The chemical sensor includes at least one sensing element 504, at least one optical excitation assembly 506 and at least one optical detection assembly 508.

FIG. 6 illustrates an embodiment of an implantable medical device (IMD) 600 with an integrated chemical sensor 603 in the header 652. The IMD 600 includes a housing or body 654. In this embodiment, the chemical sensor 603 is located in the IMD device header 652 which is in turn coupled to the housing 654. FIG. 7 illustrates an embodiment of an implantable medical device (IMD) 700 with an integrated chemical sensor 703 disposed on the device housing 754. In this embodiment, the chemical sensor 703 is coupled to the device housing 754. According to various embodiments, circuitry for correction of cardiac arrhythmias uses a common battery with the excitation assembly. Circuitry for correction of cardiac arrhythmias is configured to communicate with the detection assembly directly or indirectly, according to various embodiments.

It will be appreciated that the sensing element may take on various structural configurations. Referring now to FIG. 8, a cross-sectional view of a sensing element 800 for measuring ion concentration is shown according to some embodiments. The sensing element 800 includes an optically transparent backing layer 825, an adhesive or bonding layer 827 under the backing layer 825, an indicator element 815 attached to the membrane, and an overcoat layer 805.

The indicator element 815 can include a polymeric support matrix and one or more ion selective sensors as described more fully below. Physiological analytes can diffuse through the overcoat layer 805 and into the indicator element 815 where they can bind with the ion selective sensor to produce a fluorimetric or colorimetric response.

The backing layer 825 can be configured to provide support (e.g. stiffness and handling capability) for the sensing element 800. The backing layer 825 can be transparent and essentially impermeable to, or much less permeable than the overcoat layer 805 to the solution in which a target analyte is present, such as blood, interstitial fluid, or a calibrating solution. The backing

layer 825 can allow the signal or signals, such as the optical signals, from the indicator element 815, to pass there-through. Particularly useful materials of construction for this backing layer 825 include polymeric materials such as polyesters, polycarbonates, polysulfones including but not limited to
5 polyethersulfones and polyphenylsulfones, polyvinylidene fluoride, polymethylpentenes, and the like.

The backing layer 825 can be adhesively bonded or thermally fused to the indicator element 815. In embodiments where the backing layer 825 is adhesively bonded to the indicator element 815, the bonding adhesive can be
10 essentially transparent to light used in excitation of the sensing element 800 and to light emitted or reflected there-from. An exemplary adhesive is FLEXOBOND 431™ urethane adhesive (Bacon Co., Irvine, Calif.).

The adhesive or bonding layer 827 can serve to couple the sensing element 800 to a substrate. The adhesive or bonding layer 827 can include a
15 bonding adhesive. The bonding adhesive can be essentially transparent to light used in excitation of the sensing element 800 and to light emitted or reflected there-from. An exemplary adhesive is FLEXOBOND 431™ urethane adhesive (Bacon Co., Irvine, Calif.).

The overcoat layer 805 can include a material that is permeable to the
20 analyte of interest. The overcoat layer 805 can be opaque so as to optically isolate the indicator element 815 from the tissues surrounding the sensing element 800 *in vivo*. Alternatively, a separate opaque layer can be disposed over or under the overcoat layer 805. The overcoat layer 805 can include a polymeric material with an opacifying agent. Exemplary opacifying agents can include
25 carbon black, or carbon-based opacifying agents, ferric oxide, metallic phthalocyanines, and the like. In a particular embodiment, the opacifying agent is carbon black. Opacifying agents can be substantially uniformly dispersed in the overcoat layer 805, or in a separate layer, in an amount effective to provide the desired degree of opacity to provide the desired optical isolation. The
30 sensing element 800 can also include an opaque ink coating applied using a variety of techniques, such as an inkjet technique or an ink-screening technique. The sensing element 800 can also include a black membrane. For example, it

can include a black DURAPORE[®] membrane (available from Millipore as a white membrane which is then treated with black ink).

FIG. 9 illustrates a cross-sectional view of a sensing element 850 for measuring analyte concentration, according to various embodiments. The sensing element 850 includes a first indicator element 865 and second indicator element 870. In an embodiment, the first indicator element 865 can be an analyte indicating element while the second indicator element 870 can be an analyte insensitive element for optical referencing purpose, or more generally, as a negative control. In another embodiment, the first indicator element 865 is specific for one analyte while the second indicator element 870 is specific for a different analyte of interest. In another embodiment, indicator elements 865 and 870 can be accompanied by other indicator elements including analyte sensitive and insensitive elements forming an indicator array. In some embodiments, concentrations of a plurality of analytes can be sensed. For example, concentrations of between 1 and 20 analytes can be sensed in some embodiments.

In the embodiment shown in FIG. 9, analytes from a bodily fluid diffuse through a membrane 855 and reversibly bind with an ion selective sensor disposed within the indicator elements. Many different ion selective sensors or systems can be used. Exemplary ion selective sensors and systems are described in greater detail below. The indicator element can include a polymeric support. The polymeric support can include an ion permeable polymeric matrix. Specifically, the polymeric support can include a polymeric matrix permeable to sodium ions, potassium ions, and hydronium ions. The polymeric support can include a hydrophilic polymer. In an embodiment, the polymeric support can include one or more of cellulose, polyvinyl alcohol, dextran, polyurethanes, quaternized polystyrenes, sulfonated polystyrenes, polyacrylamides, polyhydroxyalkyl acrylates, polyvinyl pyrrolidones, polyamides, polyesters, and mixtures and copolymers thereof.

The membrane 855 can include an ion permeable polymeric matrix. For example, the membrane 855 can include a polymeric matrix permeable to sodium ions, potassium ions, and hydronium ions. In some embodiments, the

membrane 855 includes a hydrophilic polymer. Various types of polymers can be used to form the membrane 855. By way of example, the membrane can include one or more of cellulose, polyvinyl alcohol, dextran, polyurethanes, quaternized polystyrenes, sulfonated polystyrenes, polyacrylamides, polyhydroxyalkyl acrylates, polyvinyl pyrrolidones, polyamides, polyesters, and mixtures and copolymers thereof.

In some embodiments, membrane 855 is opaque. For example, in some embodiments both an optical excitation assembly and an optical detection assembly are located on a side of the sensing element 850 opposite the membrane 855. In such an embodiment, rendering membrane 855 opaque can reduce background interference. In other embodiments, an opaque cover layer is disposed over membrane 855. It will be appreciated that there are many ways of developing opacity in a membrane or layer including those described above.

The housing 860 can be configured to separate indicator elements 865 and 870. The housing 860 can include microwells or microcavities into which the indicator elements 865 and 870 fit. However, in some embodiments the indicator elements are disposed immediately adjacent to one another. The housing 860 can be constructed of various materials. In some embodiments, the housing 860 includes a polymeric matrix. In an embodiment, the housing 860 includes an ion permeable polymeric matrix. Base layer 875 is configured to be disposed between the indicator elements 865 and 870 and the optical detection assembly. In an embodiment, the base layer 875 is optically transparent over the wavelengths of interrogation and detection. Base layer 875 can be made of a variety of different materials including an optically transparent polymer, glass, crystal, etc. In some embodiments, base layer 875 is omitted such that components, such as the optical excitation assembly and/or optical detector assembly are in direct contact with indicator elements 865 and 870.

According to an embodiment, dual wavelengths of light are used for illumination of the one or more sensing elements to allow for differential measurements. For example, one center wavelength can excite the sensing element at an isobestic point on the spectral response curve and another center-wavelength can excite at a maximally sensitive wavelength. Another

embodiment can excite the sensing element(s) using dual illumination wherein the two center wavelengths are chosen for maximal excitability but with complimentary amplitude responses. The analyte insensitive optical element is then used as an optical system drift correction signal and thereby enhances long-term accuracy. Other embodiments employ pH sensitive compartments to allow for cancellation of pH effects.

FIG. 10 illustrates a cross-sectional view of a sensing element for measuring analyte concentrations, according to various embodiments. The sensing element 900 includes a first indicator element 915 and second indicator element 920. The sensing element 900 includes a housing 910, an ion permeable membrane 905, and a base layer 925. In this embodiment, the chemistries of the sensing element 900 are integrated into or onto support beads for the purpose of increasing surface area and optical scattering effects. The sensing element 900 can be configured to be mated to the header of a pulse generator, to an optical window in the housing of a pulse generator, to a lead, or to an optical window on a sensor in wireless communications with the pulse generator (satellite sensor).

FIG. 11 illustrates one embodiment of a system for measuring an analyte concentration. The analyte of interest, for example potassium, is present in a bodily fluid, for example interstitial fluid, in contact with the ion permeable membrane 586 of sensing element 578. The analyte diffuses through the membrane 586 and binds with an ion selective sensor in indicator element 580. The binding of the analyte results in an absorption spectral shift and/or a change in the fluorescent intensity of the indicator element 580.

Indicator element 584 is also subject to the flux of analyte diffusing through the membrane 586. However, in this embodiment indicator element 584 is designed to be optically invariant to analyte concentrations and thus can serve as a negative control. In this embodiment, indicator element 584 can also be referred to as an optical reference element.

The diffuse reflectance spectra of indicator element 580 and optical reference element 584 are detected by first illuminating indicator element 580 and optical reference element 584 with emitters 562 and 564 (optionally in conjunction with optical filters.) Emitters 562 and 564, located within opto-

electronic block 560, can be configured to produce light at two different center-wavelengths (e.g., wavelength 1 and wavelength 2 respectively) selected to effectively interrogate the spectral reflectance changes of indicator element 580 as the analyte concentration changes. Emitters 562 and 564 can be turned on and off alternately, under control of microprocessor control unit (MCU) 548 so that only one wavelength of reflectance is interrogated at a time. The light can be coupled from each of the emitters 562 and 564 to each of the indicator element 580 and the optical reference element 584 by means of an optical routing block 576. Diffusely reflected light, or emitted light in the case of a fluorescent sensor, is then routed from indicator element 580 and optical reference element 584, through optically transparent membrane 582, to sensor optical detector 572 and reference optical detector 532, respectively, by means of the optical routing block 576. The optical routing is achieved by means of optical fibers, waveguides, integrated optical packing of emitter and detector subassemblies, by free-space optics, or by other means known by those skilled in the art. The optical detectors 572 and 532 produce an electrical current that can be amplified by circuits 574 and 534 respectively to result in voltage signals indicative of the reflected light intensity returned from the indicator element 580 and the optical reference element 584 respectively. These analog voltage signals can then be processed by A/D converters 544 and 542, respectively, to produce digital signals and can then be routed through a multiplexer (MUX) 540. The resulting data is processed by MCU 548 and stored in memory 550 or routed to telemetry unit 552.

As the concentration of the analyte changes, the optical characteristics of indicator element 580 change, while the optical characteristics of the optical reference element 584 do not change. In one embodiment, MCU 548 can take the digitized emission or reflectance signal at a particular wavelength associated with excitation of the indicator element 580 and then calculates a corrected signal based upon the digitized signals associated with optical reference element 584. The MCU 548 can then take the digitized emission or reflectance signal at a second wavelength associated with excitation of the indicator element 580 and calculates a second corrected signal based upon the digitized signals associated

with optical reference element 584. The MCU 548 can then use the ratio of corrected optical signals at the two wavelengths in estimating analyte concentration. This ratio is processed by MCU 548 by a program routine or lookup table into representations of analyte concentration. Resulting data can be stored, transmitted to external devices, or integrated into the functions of an accompanying therapeutic device.

Embodiments of chemical sensors of the invention may be calibrated initially and/or periodically after implantation to enhance accuracy. It will be appreciated that calibration can be performed in various ways. By way of example, after the chemical sensor is implanted, blood can be drawn and analyte concentrations in the blood can be assessed using standard *in vitro* laboratory techniques. The concentrations indicated by the *in vitro* testing can then be compared with the concentrations indicated by the implanted device, and the implanted device can then be corrected (offset correction) based on the difference, if any. The offset correction value can be stored in circuitry in the pulse generator and automatically applied to future measurements. In some embodiments, this correction procedure is performed after the foreign body response has formed a tissue pocket around the implanted device. In some embodiments, this correction procedure is performed at regular intervals.

The chemical sensor can measure the concentration of one or more analytes, such as sodium ions and potassium ions, at a programmable rate (using a programmable timer), according to an embodiment. The chemical sensor can also be configured to measure concentrations of analytes on demand, as dictated by a program routine or as initiated by an externally communicated command. The analyte concentration measurements can be equally spaced over time, or periodic, in an embodiment. For example, the optical excitation assembly can be configured to interrogate the sensing element periodically. The measurements can be taken at various times in a non-periodic manner, or intermittently, in an embodiment. In one embodiment, a measurement is made approximately once per hour.

The power consumption of an optical chemical sensor system can be significantly greater than that of an electrochemical sensor system configured for

similar performance. This is particularly true in the context of an optical chemical sensor including an optical excitation assembly. Chemical sensors of the invention can be designed as part of a chronically implantable system and therefore power consumption can be a performance limiting characteristic. As
5 such, embodiments of the invention can include methods to reduce average and peak power consumption from an energy source, such as a battery.

Referring now to FIG. 12, a schematic illustration of a power management system is shown that can reduce battery load while preserving system performance. In FIG. 12, interval "A" depicts the duration of
10 observation of the sensed parameter. Interval "B" depicts the maximum duration between observations of the sensed parameter. Interval "B" should be as long as possible for the best energy savings, but it must be short enough so that rapid changes in the observed system are tracked by the detector. It will be understood that this system can be optimized based on the temporal
15 characteristics of the analyte of interest. For example, if the sensor is intended to measure potassium levels, the maximum rate of change for potassium concentrations in the target physiological system can be taken into account. In other words, the particular analyte being measured can directly impact factors such as the maximum duration between observations of the sensed parameter. In
20 an embodiment, the LED can be turned on for a portion of the duration of observation. The percentage of time that the LED is turned on during the duration of observation can be referred to as the duty factor of sampling.

The ratio of A/B multiplied by the duty factor of sampling represents the fraction of energy used by the system compared to a continuous mode detection
25 scheme. For example, assuming the duration of observation is 100 milliseconds, the maximum duration between observations is 3600 seconds (1 hour), and the duty factor is 50%, then the final energy fraction is 0.0000138. In other words, based on these assumptions, the sensor will use approximately 1/72,000th of the energy in a semi-continuous duty factor mode than in continuous mode. It will
30 be appreciated that many different durations of observation are contemplated herein. In addition, many different maximum durations between observations are contemplated herein such as 1 minute, 10 minutes, 30 minutes, 60 minutes,

120 minutes, 180 minutes, etc.

In many embodiments, the dominant energy consuming portion of the sensor system will be the light source, if operated in a continuous mode. A typical light source can consume 2 milliAmps, an amount unacceptably high for most chronically implanted devices. However, using the described duty factoring scheme, in one example, the average current consumed can be reduced to 28 nanoAmps. It will be appreciated that the results of the duty factoring scheme will depend on various factors including the particular duration of observation, the maximum duration between observations, and the effective duty factor.

Embodiments of the invention can also include methods for reducing noise and uncertainty in the system responses including modulation/demodulation and multiple sampling events. Modulation reduces the sensor susceptibility to external light sources and to DC offsets in the received signal. By way of example, the stimulating light source can be turned on at a specific frequency 1204 “frequency f” and the receive circuit can have a filter that rejects signals outside of a narrow band that includes frequency f. In addition, the receive circuit includes a demodulator that responds preferentially to signals of frequency f. These features can reduce or eliminate any system response to signals from sources other than the intended optical source.

Multiple sampling events 1202 within the sampling interval provide lower peak current demands from the power supply during the sample event. These also provide multiple signals which can be integrated and averaged to reduce the effects of random noise sources and increase accuracy. The generation of sample intervals, sample events, and the processing of the sensor information can be performed by a microprocessor control unit / timer. The microprocessor control unit can then send the data to memory or communicate with other components of a patient management system.

Embodiments of the invention can include a sensing element including one or more ion selective sensors. Ion selective sensors may either rely on surface phenomena or on concentration changes inside the bulk of a phase. Ion

selective sensors can include optical sensors, including both non-carrier optical sensors and carrier-based optical sensors, and ion-selective electrodes (ISEs).

In an embodiment, the ion selective sensor is fluorimetric. Fluorimetric ion selective sensors exhibit differential fluorescent intensity based upon the
5 complexing of an analyte to a complexing moiety. In an embodiment, the ion selective sensor is colorimetric. Colorimetric ion selective sensors exhibit differential light absorbance based upon the complexing of an analyte to a complexing moiety.

In some embodiments, the ion selective sensor comprises a non-carrier or
10 carrier-based fluorescent or colorimetric ionophoric composition that comprises a complexing moiety for reversibly binding an ion to be analyzed, and a fluorescing or colorimetric moiety that changes its optical properties as the complexing agent binds or releases the ion. The complexing agents of the invention can optionally be appended with one or more organic substituents
15 chosen to confer desired properties useful in formulating the ion sensing composition. By way of example, the substituents can be selected to stabilize the complexing agent with respect to leaching into the solution to be sensed, for example, by incorporating a hydrophobic or polymeric tail or by providing a means for covalent attachment of the complexing agent to a polymer support
20 within the ion selective sensor.

Non-Carrier Ion Sensors

In an embodiment, the ion selective sensor is a non-carrier optical ion sensor. Non-carrier optical ion sensors can include a hydrophilic indicator dye
25 that is covalently attached to a hydrophilic polymer matrix (substrate), and which selectively complexes the ion of interest to directly produce either a colorimetric or fluorescent response. In an embodiment of a non-carrier ion selective sensing element, a fluoroionophore is covalently bonded to a suitable substrate. A fluoroionophore is a compound including both a fluorescent moiety
30 and an ion complexing moiety. As an example, (6,7-[2.2.2]-cryptando-3-[2''-(5''-carboethoxy)thiophenyl]coumarin, a potassium ion selective fluoroionophore, can be covalently attached to an azlactone functional

hydrophilic porous polyethylene membrane to produce a fluorescence-based K^+ non-carrier ion sensor. As another example, hydroxypyrene trisulfonate, a hydrogen ion selective fluoroionophore, can be covalently attached to an amine functional cellulose to produce a fluorescence-based pH non-carrier ion sensor.

5 The fluoroionophore can be covalently bonded to a substrate by any useful reactive technique, which may depend upon the chemical functionality of the particular fluoroionophore. The substrate can, in turn, be attached to a backing membrane or layer.

A specific example of a non-carrier potassium ion sensor includes a
10 sensing layer that includes 6,7-[2.2.2]-cryptando-3-[2''-(5''-carboxy)furyl]coumarin (FCCC) covalently bonded to a crosslinked amine functional cellulose membrane (CUPROPHANTM; Enka AG, Ohderstrasse, Germany), the sensing layer being adhered to a polycarbonate backing membrane by FLEXOBOND 430TM urethane adhesive and the backing
15 membrane having coated thereon CW14TM pressure-sensitive adhesive on a release liner. Another specific example of a non-carrier potassium ion sensor includes a sensing layer that includes 6,7-[2.2.2]-cryptando-3-[2''-(5''-carboxy)furyl]coumarin covalently bonded to a crosslinked azlactone functional hydrogel with a linker such as a diamine linker. The sensing layer can then be
20 photocrosslinked within the cavity of a substrate, such as a microwell, or the gel capsule of a satellite sensor. The term satellite sensor can be used to describe implanted chemical sensors that are remote from the pulse generator.

A specific example of a non-carrier sodium ion sensor includes a sensing layer having 6,7-[2.2.1]-cryptando-3-[2''-(5''-carboxy)furyl]coumarin covalently
25 bonded to a crosslinked amine functional cellulose membrane (CUPROPHANTM; Enka AG, Ohderstrasse, Germany), the sensing layer being adhered to a polycarbonate backing membrane by FLEXOBOND 430TM urethane adhesive and the backing membrane having coated thereon CW14TM pressure-sensitive adhesive on a release liner.

30 A specific example of a non-carrier hydrogen ion sensor includes a sensing layer that includes hydroxypyrene trisulfonate covalently bonded to a crosslinked amine functional cellulose membrane (CUPROPHANTM; Enka AG,

Ohderstrasse, Germany), the sensing layer being adhered to a polycarbonate backing membrane by FLEXOBOND 430TM urethane adhesive and the backing membrane having coated thereon CW14TM pressure-sensitive adhesive on a release liner.

5 An exemplary class of fluoroionophores are the coumarocryptands. Coumarocryptands can include lithium specific fluoroionophores, sodium specific fluoroionophores, and potassium specific fluoroionophores. For example, lithium specific fluoroionophores can include (6,7-[2.1.1]-cryptando-3-[2''-(5''-carboethoxy)furyl]coumarin. Sodium specific fluoroionophores can
10 include (6,7-[2.2.1]-cryptando-3-[2''-(5''-carboethoxy)furyl]coumarin. Potassium specific fluoroionophores can include (6,7-[2.2.2]-cryptando-3-[2''-(5''-carboethoxy)furyl]coumarin and (6,7-[2.2.2]-cryptando-3-[2''-(5''-carboethoxy)thiophenyl]coumarin.

 Suitable fluoroionophores include the coumarocryptands taught in U.S.
15 Pat. No. 5,958,782, the disclosure of which is herein incorporated by reference. Such fluorescent ionophoric compounds can be excited with GaN blue light emitting diodes (LEDs) emitting light at or about 400 nm. These fluorescent ionophoric compounds have ion concentration dependent emission that can be detected in the wavelength range of about 450 nm to about 470 nm.

20 The substrate can be a polymeric material that is water-swellaable and permeable to the ionic species of interest, and insoluble in the medium to be monitored. Exemplary substrate materials include, for example, ion-permeable cellulose materials, high molecular weight or crosslinked polyvinyl alcohol (PVA), dextran, crosslinked dextran, polyurethanes, quaternized polystyrenes,
25 sulfonated polystyrenes, polyacrylamides, polyhydroxyalkyl acrylates, polyvinyl pyrrolidones, hydrophilic polyamides, polyesters, and mixtures thereof. In an embodiment, the substrate is cellulosic, especially ion-permeable crosslinked cellulose. In an embodiment, the substrate comprises a regenerated cellulose membrane (CUPROPHANTM, Eenka AG, Ohderstrasse, Germany) that
30 is crosslinked with an epoxide, such as butanediol diglycidyl ether, further reacted with a diamine to provide amine functionality pendent from the cellulose polymer. In an alternate embodiment, the substrate comprises azlactone

functional hydrophilic porous polypropylene that has been amine functionalized using a diamine functionality pendent to the azlactone.

In one approach to making a non-carrier ion selective sensor, aminoethylated cellulose is first activated by treatment with a sodium bicarbonate solution. A fluoroionophore, such as 6,7-[2.2.2]-cryptando-3-[2''-(5''-carboxyl)furyl]coumarin, is then covalently bonded to the aminoethylated cellulose. Optionally, once the desired amount of the fluoroionophore is covalently bonded to the aminoethylcellulose, remaining amino groups are blocked by acylation. Next, the fluoroionophore bearing cellulose is then taken up into solution and then coated or deposited on an optical fiber or in a microcavity of a housing.

Permeability enhancing agents can be added to the composition used to form the sensing layer to increase the ion permeability of the sensing layer. Suitable permeability enhancing agents can include small molecular weight molecules which are hydrophilic and are water soluble. Such agents can include sugars, polyols and the like. As a specific example, glycerol can be used. Another specific example includes low molecular weight water soluble polyvinylalcohol.

In some embodiments, the sensing layer materials can be prepared utilizing a photocrosslinkable hydrogel having reactive functional groups for covalently attaching chemically functionalized fluoroionophores and chromoionophores. In an embodiment, the photocrosslinkable hydrogel can include azlactone functional copolymers. The azlactone functional copolymers can be crosslinked (cured) using photocrosslinking agents such as bisazides, bisdiazocarbonyls, and bisdiazirines. This type of crosslinking does not affect the azlactone groups, but creates a three dimensional hydrogel matrix. The azlactone functional polymers can then be reacted with chromoionophores or fluoroionophores having reactive functional groups (such as primary amines, secondary amines, hydroxyl groups, and thiol groups). The reactive functional groups then react, either in the presence or absence of suitable catalysts, with the azlactones by nucleophilic addition to produce a covalent bond. The covalent bonding step can be carried out before or after coating, before or after curing,

and before or after patterning.

Optionally, after ion sensing molecules are covalently attached, capping groups can be added to occupy any unused functional groups, such as azlactone groups, and prevent later contamination of the gel by any unwanted material.

- 5 The capping group may hydrophilic (e.g. water) to improve the swellability of the gel. Alternatively, the capping group can be hydrophobic to provide a microenvironment compatible with carrier based ion selective sensors, as described more fully below.

10 The sensing layer materials can be configured in various ways depending on the particular application. In some embodiments, the sensing layer materials are configured in a substantially planar configuration. In other embodiments, the sensing layer materials are configured as beads or microdots.

15 Curing of sensing layer compositions can be performed using light or heat depending on the particular application and the chemical makeup of the sensing layer materials.

Carrier Based Ion Sensors

In an embodiment, the ion selective sensor is a carrier based ion sensor. Carrier based ion sensors include a compound, referred to as an ionophore, that
20 complexes with and serves to carry the ion of interest. Carrier based ion sensors can include both optical ion sensors and ion selective electrodes. In some embodiments, carrier based optical ion sensors include a lipophilic ionophore, and a lipophilic fluorescent or colorimetric indicator dye, called a chromoionophore. The chromoionophore and the ionophore can be dispersed in,
25 and/or covalently attached to, a hydrophobic organic polymeric matrix. The ionophore can be capable of reversibly binding ions of interest. The chromoionophore can be a proton selective dye. In operation, ions of interest are reversibly sequestered by the ionophores within the organic polymer matrix. To
30 maintain charge neutrality within the polymer matrix, protons are then released from the chromoionophore, giving rise to a color or fluorescence change.

A specific example of a carrier based ion sensor includes potassium ionophore III, chromoionophore I, and potassium tetrakis(4-chlorophenyl)borate

dispersed in a polymer matrix made from polyvinylchloride and bis(2-ethylhexyl)sebacate surfactant to produce a colorimetric K^+ sensing element.

The hydrophobic organic polymeric matrix can include materials with sufficient tensile strength, chemical inertness, and plasticizer compatibility.

5 Exemplary materials can include poly(vinyl chloride), derivatives of polyvinyl chloride, polyurethane, silicone rubbers, polyalkylmethacrylates, and polystyrene.

In an embodiment, the hydrophobic organic polymer matrix is made permeable to the analyte of interest with plasticizers. Suitable plasticizers can
10 include 2-nitrophenyl octyl ether (NPOE), dioctyl sebacate (DOS), bis(2-ethylhexyl)sebacate (BEHS), dibenzyl ether (DBE), and the like. However, it is known that plasticizers can leach out of the hydrophobic organic polymer matrix over time. This may lead to decreased functioning of the sensor. Accordingly, in some embodiments, the sensing element includes a polymeric matrix that is
15 self-plasticizing. Such polymers can include polyurethanes, polysiloxanes, silicone rubber, polythiophenes, epoxyacrylates, and methacrylic and methacrylic-acrylic copolymers. In an embodiment, ion selective polymer materials are produced with an acrylate backbone and a plurality of pendant lipophilic plasticizing groups derived from acrylate co-monomers. The
20 lipophilic plasticizing groups can, for example be a pendant C_{3-7} alkyl group that renders the polymer matrix inherently soft (e.g. a glass transition temperature (T_g) of less than -10 °C) and does not require additional plasticizers, i.e. the polymer is in effect self-plasticizing, so that the problem of leaching of the plasticizer does not arise.

25 In some embodiments, a lipophilic anion (ion-exchanger) is included to improve ion selectivity by stabilizing the concentration of the ion-ionophore complex. For example, tetraphenylborate derivatives can be used as an ion-exchanger in cation-selective polymer membrane electrodes and bulk optical sensors. In addition to reducing anion interference, tetraphenylborates can also
30 decrease membrane resistance, and improve ionophore selectivity by stabilizing the concentration of ion-ionophore complex. The delocalized monoanionic charge that these compounds possess, in combination with their sterically

hindered molecular structure make them very weakly coordinating. This is a characteristic that leads to weak, non-specific ion pair formation and maximum ionophore-mediated selectivity of the membrane. Specific lipophilic anions can include potassium tetrakis(4-chlorophenyl)borate), designated KTpCIPB; 5 sodium tetrakis[3,5-bis(1,1,1,3,3,3-hexafluoro-2-methoxy-2-propyl)phenyl]borate, designated NaHFPB; potassium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate, designated KTFPB; sodium tetrakis(4-fluorophenyl)borate, combinations thereof, and the like. Compounds that can be suitable alternatives to tetraphenylborates include 3,5[bis- 10 (trifluoromethyl)phenyl]borate (NaTFPB), carboranes (such as closo-dodecacarboranes), and halogenated carboranes (such as trimethylammonium undecabromocarborane (TMAUBC), undecachlorinated (UCC), hexabrominated (HBC), and undecaiodinated (UIC) carborane anions).

The chromoionophore in a carrier based ion sensor, as mentioned above, 15 can be a pH sensitive material. Exemplary pH sensitive chromoionophore dyes include include congo red, neutral red, phenol red, methyl red, lacmoid, tetrabromophenolphthalein, α -naphtholphenol, and the like. The chromoionophore can be immobilized by covalent bonding to the polymer matrix. The chromoionophore can be dissolved into the polymer matrix with the aid of a 20 plasticizer as described above.

The ionophore and/or chromoionophore can be immobilized in the polymeric matrix in various ways. For example, in one approach the ionophore is directly grafted onto an existing polymer with reactive sites. In a second approach, two different polymers are blended together, with one of them 25 containing the graft ionophore. A third approach includes polymerizing an acrylate functional monomer, including the ionophore as a side chain, with other monomers in a one-step polymerization method. In a fourth approach, azlactone functional acrylate polymers can undergo nucleophilic addition of an amine, hydroxyl, or thiol functional ionophores to provide a covalently bonded 30 ionophore.

Exemplary pH responsive chromoionophores can include Chromoionophore I, (9-(diethylamino)-5-(octadecanoylimino)-5H-

benzo[a]phenoxazine), "ETH 5294" CAS No. 125829-24-5; Chromoionophore II, (9-diethylamino-5-[4-(16-butyl-2,14-dioxo-3,15-ioxaeicosyl)phenylimino]benzo[a]phenoxazine), "ETH 2439" CAS No. 136499-31-5; Chromoionophore III, (9-(diethylamino)-5-[(2-octyldecyl)imino]benzo[a]phenoxazine, "ETH 5350" CAS No. 149683-18-1; Chromoionophore IV, (5-octadecanoyloxy-2-(4-nitrophenylazo)phenol), "ETH 2412" CAS No. 124522-01-6; Chromoionophore V, (9-(diethylamino)-5-(2-naphthoylimino)-5H-benzo[a]phenoxazine), CAS No. 132097-01-9; Chromoionophore VI, (4',5'-dibromofluorescein octadecylester), "ETH 7075" CAS No. 138833-47-3; Chromoionophore XI, (fluorescein octadecyl ester), "ETH 7061" CAS No. 138833-46-2.

In an embodiment, the ion selective sensor is a carrier based ion-selective electrode (ISE). Carrier based ion-selective electrodes can include many of the same materials as carrier based optical ion sensors, but without the chromoionophore. In this embodiment, the ion selective hydrophobic polymer matrix containing the ionophore can be placed on top of a reference electrode such as a Ag/AgCl electrode, with an intervening hydrogel layer containing a fixed amount of a reference electrolyte (e.g. KCl for a K⁺ sensor). A reference electrode without the ionophore is also provided in this embodiment. ISEs produce a measurable potentiometric change upon contact with a fluid sample containing target ions. This is driven by phase boundary potentials at both interfaces, and the diffusion potential within the ion-selective polymer matrix.

Complexing Moieties

Compounds used in both non-carrier ion sensors and carrier-based ion sensors can include complexing moieties. Suitable complexing moieties can include include cryptands, crown ethers, bis-crown ethers, calixarenes, noncyclic amides, and hemispherand moieties as well as ion selective antibiotics such as monensin, valinomycin and nigericin derivatives.

Those of skill in the art can recognize which cryptand and crown ether moieties are useful in complexing particular cations, although reference can be made to, for example, Lehn and Sauvage, "[2]-Cryptates: Stability and

Selectivity of Alkali and Alkaline-Earth Macrocyclic Complexes,” J. Am. Chem. Soc, 97, 6700-07 (1975), for further information on this topic. Those skilled in the art can recognize which bis-crown ether, calixarene, noncyclic amides, hemispherand, and antibiotic moieties are useful in complexing particular cations, although reference can be made to, for example, Buhlmann et al., “Carrier-Based Ion-Selective Electrodes and Bulk Optodes. 2. Ionophores for Potentiometric and Optical Sensors,” Chem. Rev. 98, 1593-1687 (1998), for further information on this topic.

By way of example cryptands include a structure referred to as a cryptand cage. For cryptand cages, the size of the cage is defined by the oxygen and nitrogen atoms and the size makes cryptand cages quite selective for cations with a similar diameter. For example a [2.2.2] cryptand cage is quite selective for cations such as K^+ , Pb^{+2} , Sr^{+2} , and Ba^{+2} . A [2.2.1] cryptand cage is quite selective for cations such as Na^+ and Ca^{+2} . Finally, a [2.1.1] cryptand cage is quite selective for cations such as Li^+ and Mg^{+2} . The size selectivity of cryptand cages can aid in the sensitivity of chemical sensing. When these cryptand cages are incorporated into physiologic sensing systems heavier metals such as Pb^{+2} and Ba^{+2} are unlikely to be present in concentrations which interfere with the analysis of ions of broader physiological interest such as Na^+ and K^+ .

For crown-ether moieties the size of the 15-crown-5 cage defined by the oxygen atoms make the unit suitably selective for Na^+ ; the size of the 18-crown-6 cage makes it suitably selective for K^+ ; the size of the 21-crown-7 cage makes it quite selective for K^+ and nonselective for Na^+ . Li^+ fits well into the cavities formed by crown ethers of sizes in the range of 12-crown-4 to 15-crown-4.

Crown ethers can include lithium specific crown ethers, sodium specific crown ethers, potassium specific crown ethers, and calcium specific crown ethers. For example, lithium specific crown ethers can include 6,6-dibenzyl-14-crown-4, (7-tetradecyl-2,6,9,13-tetraoxatricyclo[12.4.4.0^{1,14}]docosane, and ((2S,3S)-(-)-2,3-bis(diisobutylcarbamoylmethyl)-1,4,8,11-tetraoxacyclotetradecane. Sodium specific crown ethers can include (2,6,13,16,19-pentaoxopentacyclo[18.4.4.4^{7,12}.0^{1,20}0^{7,12}]dotriacontane, designated 2,3:11,12-didecalino-16-crown-5 or “DD16C5”; 4’isopropyl-4’-OCH₂CON(C₈H₁₇)₂ -

dibenzo-16-crown-5, designated Na⁺-18; 4'-decanyl-4'-(4-hydroxy-5-methyl-nitrophenyl-5-oyl)-dibenzo-16-crown-5, designated Na⁺ 43; and 15-methyl-15-stearyl-oxymethyl-1,4,7,10,13-pentaoxacyclohexadecane, designated "ODM16C5". Potassium specific crown ethers can include naphtho-(15-crown-5); (hexanolyloxymethyl)benzo-15-crown-5; (octadecanoyloxymethyl)benzo-15-crown-5; and K⁺-35, an anionic crown ether dye derived from benzo-15-crown-5 (nomenclature of Buhlmann et al. *supra*). Calcium specific crown ethers can include 4,13-di-N-octadecylcarbamoyl-3-oxabutyryl-1,7,10,16,tetra-oxa-4,13-diazacyclooctadecane or 10,19-bis[(octadecylcarbamoyl)methoxy-acetyl]-1,4,7,13,16-pentaoxa-10,19-diazacycloheneicosane; designated "K22E1".

Complexation of bis-(crown ether) and alkali metal ions is quite specific when the size of the cation is slightly larger than the internal cavity formed by one of the crown ether rings. This can be explained by formation of intramolecular sandwich complexes. High Na⁺ selectivity is, for example, obtained with bis(14-crown-4) and bis(12-crown-4) compounds, even though the 14-crown-4 and 12-crown-4 cavities too small for Na⁺. In the same way, K⁺ selectivity is obtained with bis(15-crown-5) compounds. Bis-crown ethers can include sodium specific bis crown ethers and potassium specific bis crown ethers. Sodium specific bis crown ethers can include bis[(12-crown-4)methyl]-2-dodecyl-2-methyl-malonate; bis[(12-crown-4)methyl]-2,2-dibenzyl-malonate; 1,1-bis[(12-azacrown-4)-N-methyl] dodecane. Potassium specific bis crown ethers can include bis[(benzo-15-crown-5)-4'-ylmethyl]pimelate; bis[(benzo-15-crown-5)-4'ylmethyl]-2-dodecyl-2-methylmalonate; and 2,2-bis[3,4-(15-crown-5)-2-nitrophenylcarbamoxymethyl]tetradecane, designated "BME-44".

Hemispherands can be considered to be crown ether compounds with an extra bridge that enhances ligand preorganization. An example of sodium specific hemispherand can include the compound sold under the trade name HEMISODIUM (Na⁺-40, nomenclature of Buhlmann et al. *supra*). Potassium specific hemispherands can include K⁺-26 (nomenclature of Buhlmann et al. *supra*) and K⁺-27 (nomenclature of Buhlmann et al. *supra*).

Non-cyclic amides can include both sodium specific non-cyclic amides and calcium specific non-cyclic amide. Sodium specific non-cyclic amides can

include N,N',N''-triheptyl-N,N',N''-trimethyl-4,4',4''-propylidynetris(3-oxabutamide), designated "ETH 227"; N,N'-dibenzyl-N,N'-diphenyl-1,2-phenylene-dioxydiacetamide, designated "ETH 157"; N,N,N',N'-tetracyclohexyl-1,2-phenylenedioxy-diacetamide, designated "ETH 2120"; and
 5 4-octadecanoyloxymethyl-N,N,N',N'-tetracyclohexyl-1,2-phenylenedioxy-diacetamide, designated "ETH 4120". Calcium specific non-cyclic amides can include (-)-(R,R)-N,N'-bis-[11-(ethoxycarbonyl)undecyl]-N,N'-4,5-tetramethyl-3,6,-dioxaoctane-diamide, designated "ETH 1001"; N,N,N',N'-tetracyclohexyl-3-oxapentanediamide, "designated ETH 129"; N,N-dicyclohexyl-N',N'-
 10 dioctadecyl-3-oxapentanediamide, "designated ETH5234".

Calixarenes can include sodium specific calixarenes and potassium specific calixarenes. Sodium specific calix[4]arenes can include 25,26,27,28-tetrakis(ethoxycarbonylmethoxy), 3,9,15,21-tert-butylcalix[4]arene; Na⁺-20 (nomenclature of Buhlmann et al. *supra*); Na⁺-42 (nomenclature of Buhlmann et al. *supra*); Na⁺-33 (nomenclature of Buhlmann et al. *supra*); and Na⁺-34
 15 (nomenclature of Buhlmann et al. *supra*). Potassium specific calix[6]arenes and calix[4]arenecrown-5 ionophores can include 37,38,39,40,41,42-hexakis(ethoxycarbonylmethoxy)calix[6]arene; K⁺-32 (nomenclature of Buhlmann et al. *supra*); K⁺-33 (nomenclature of Buhlmann et al. *supra*); and K⁺-
 20 34 (nomenclature of Buhlmann et al. *supra*).

Coating and Patterning of Sensors

Sensing layer compositions, in the context of both carrier and non-carrier ion sensors, can be coated with or without addition of a solvent. In some
 25 embodiments, the sensing layer components are formulated as a liquid composition to facilitate coating of the sensing layer components onto substrates using coating techniques such as spray coating or dip coating. For example, in certain embodiments, it can be advantageous to incorporate the sensing layer on the tip of a fiber optic lead or inside a capsule associated with a satellite sensor
 30 in wireless communication with a pulse generator. In these cases, it can be advantageous to spray coat or dip coat the sensing layer components onto the fiber optic lead or inside the capsule. Suitable coating methods can also include

spin coating, knife coating, or roller coating.

The composition can be selectively coated to provide a patterned surface. For example, techniques including ink jet printing, offset, flexographic printing, etc. can be used to selectively coat the composition. The composition may also
5 be knife coated onto a microstructured surface (e.g. a surface having micron scale depressions or channels) in such a way that the composition resides in microstructures, providing a patterned array of the composition. In some
embodiments, the composition can be deposited into microwells or microcavities in a substrate using precision dispensing techniques, such as pin-based precision
10 dispensing.

Beyond selective coating, patterning can also be achieved by techniques such as selective curing of the composition or selective removal of the composition from a substrate. Selective curing techniques can include selective exposure to UV light or heat. Selective UV exposure methods include exposure
15 through a mask or photographic negative or exposure by a directed beam of light, such as a laser. After curing, remaining uncured composition can be removed, e.g. by washing, to result in a patterned coating.

In some embodiments, the composition can be patterned onto a substrate by a laser addressable thermal transfer imaging processes. In this process, a
20 thermal transfer donor element is constructed comprising a support layer, a light-to-heat conversion layer, and a transfer layer comprising the composition to be patterned. When the donor element is brought in contact with a receptor and image wise irradiated, a melt stick transfer process occurs and the composition containing transfer layer is imaged onto the receptor. As an example, the
25 photocrosslinkable azlactone composition described earlier can be used in the transfer layer of such a system. This photocrosslinkable azlactone composition can be reacted with chromoionophores or fluoroionophores before incorporation into the transfer layer, after incorporation into the transfer layer, or after laser addressed thermal transfer to the receptor. The azlactone composition can be
30 thermally or photochemically crosslinked before or after the transfer process. This process offers the opportunity to pre-pattern different indicator elements onto a transfer layer comprising the azlactone composition prior to laser

addressed thermal imaging of individual azlactone-indicator conjugates to the receptor substrate. Registration of the donor and receptor elements can be robotically altered between any or all of the transfer steps to build up desired array spacings and sizes for transferred elements on the receptor that is different
5 from the patterning of the indicators on the transfer layer.

Methods of Operation

An embodiment of the invention includes a method for using an implantable medical device including a pulse generator to monitor
10 concentrations of physiological analytes. The method includes sensing analyte concentrations with a chemical sensor. Sensing analyte concentrations with a chemical sensor can include exposing a sensing element to a bodily fluid. Sensing analyte concentrations with a chemical sensor can also include illuminating a sensing element with an optical excitation assembly to produce an
15 optical return signal. Sensing analyte concentrations with a chemical sensor can further include receiving light reflected from or emitted from the sensing element using an optical detection assembly.

Methods of the invention can include periodically interrogating a sensing element to determine analyte concentrations. Methods can also include storing a
20 digitized representation of measured analyte concentrations in a memory within the implantable medical device. In some embodiments, once the information is stored, it can be evaluated as a function of time to identify metabolic trends and events. Some embodiments also include conveying data regarding analyte concentrations and/or calculated risk indexes to another device. For example,
25 one or more messages can be wirelessly communicated to a remote patient monitoring device, including information on the stored measured analyte concentrations. In some embodiments, the method includes reading analyte concentration periodically using a home monitoring system, such as an advanced patient management system (APM). A further embodiment includes providing
30 trending data to show the trend of analyte concentration over time.

According to various method embodiments, a processor within the implantable medical device can be used to calculate analyte concentrations

based on digitized optical signals collected from an optical sensing element and a corresponding analyte insensitive optical reference element. The method can include first correcting analyte dependent intensity readings from a sensing element at a given center-wavelength for optical offsets as measured using
5 intensity readings from an optical reference element at that center-wavelength. The method can also include using the corrected optical signal, in conjunction with a lookup table to obtain the analyte concentration. In an embodiment, the method includes adjusting the data based on calibration coefficients stored in the memory. In various embodiments, adjustments are made based on temperature,
10 as measured by a temperature sensor integrated into the implantable medical device. The method can also include calculating compensated analyte concentrations, taking into account various adjustments, and then storing them in memory along with an associated time stamp.

15 Methods of Use

In some current heart failure monitoring regimens, heart failure patients take note of weight gain, blood pressure, and other symptoms, and then self-report these symptoms via telephone to a nurse or physician who treats their condition. If their reported symptoms indicate an adverse condition that requires
20 diuretic therapy, the caregiver has to choose between prescribing treatment over the phone, or bringing the patient to the clinic. Diuretic therapy can include the administration of diuretics as well as the administration of agents such as ACE inhibitors, beta blockers, ionotropic agents, in various combinations.

A common recommendation, often given without a blood test to measure
25 concentrations of physiological analytes, is to administer an increased dose of diuretics and a dose of potassium. The logic of administering the dose of potassium is that it is used to offset increased losses of physiological potassium due to the increased dose of diuretics. Because actual physiological potassium concentrations are unknown in this scenario, there is a risk that the patient will
30 end up with a potassium concentration that is too high or too low as a result. Specifically, if the patient already had high potassium levels, unknown to the caregiver, and if potassium ingestion and excretion are not properly balanced,

then it is possible to suffer from hyperkalemia (potassium concentration too high). The consequences of hyperkalemia, as previously described, can include cardiac arrhythmias that sometimes result in death.

In an embodiment, the invention includes a method of monitoring diuretic therapy (such as diuretic therapy administered to a patient) using an implanted medical device. The method can include optically monitoring potassium ion concentration in a bodily fluid of a patient using an implanted medical device. The method can include determining whether the patient is suffering from hypokalemia or hyperkalemia. In an embodiment, the patient is a heart failure patient. The method includes monitoring potassium concentrations with a chemical sensor. Monitoring potassium concentrations with a chemical sensor can include exposing a sensing element to a bodily fluid. Monitoring potassium concentrations with a chemical sensor can also include illuminating a sensing element with an optical excitation assembly to produce an optical return signal. Monitoring potassium concentrations with a chemical sensor can further include receiving light reflected from or emitted from the sensing element using an optical detection assembly. Some embodiments of the method also include conveying data regarding potassium concentrations and/or calculated risk indexes to a non-implant device via a telemetry link and/or to a health professional. For example, one or more messages can be wirelessly communicated to a remote patient monitoring device.

Methods of monitoring diuretic therapy using an implanted medical device according to the invention can provide various benefits. One benefit is that a caregiver can more safely recommend a therapeutic dose of a diuretic and potassium while reducing the risk of hyperkalemia and hypokalemia. The method can allow the correct balance of diuretic and potassium to be prescribed without drawing blood from the patient. The information gathered by the implanted device can be coupled through a telemetry/remote patient management system, allowing the patient to get the optimal prescription without entering the physician's office.

In addition, the risk posed to a patient by administering increased doses of diuretics along with doses of potassium can be compounded by the patient's

overall renal function. For patients with impaired renal function, the risk of becoming hyperkalemic from a dose of potassium is much greater. Even a slight potassium dose imbalance, that would be completely safe for a patient with normal kidney function, could have catastrophic destabilizing effects on a patient with impaired renal function. Therefore, methods of monitoring diuretic therapy using an implanted medical device according to some embodiments of the invention can also include optically monitoring a concentration of an analyte indicative of renal function with the implanted medical device. Specific analytes indicative of renal function can include creatinine, urea, and uric acid.

5
10
15
20
25
30

While an example of a method of monitoring diuretic therapy has been described, it will be appreciated that embodiments of the present invention can also include monitoring of other types of therapy. By way of example, embodiments of the invention can include a method for titrating drug therapy. In particular, an embodiment can include a method for controlling delivery of an active agent into a human body. The method can include measuring a physiological concentration of one or more analytes with an implanted system and varying delivery of the substance at least in part as a function of the measured concentration of the one or more analytes. The implanted system can include a pulse generator and a chemical sensor. The chemical sensor can include a sensing element, an excitation assembly, and a detection assembly. The one or more analytes can include potassium, sodium, chloride, calcium, magnesium, lithium or hydronium. The one or more analytes can include an analyte indicative of renal function. The one or more analytes can include an analyte indicative of cardiac function. In an embodiment, the active agent can comprise a diuretic. The physiological concentration of the one or more analytes can be assessed by measuring the concentration in a bodily fluid selected from the group including of blood, interstitial fluid, serum, lymph, and serous fluid.

Methods of the invention can also include providing cardiac arrhythmia therapy to a patient. By way of example, methods of the invention can include optically sensing a physiological concentration of an ion in a bodily fluid of a patient with an implanted chemical sensor. The method can further include communicating data regarding the physiological concentration of an ion to an

implanted pulse generator. The method can also include altering the delivery of pulses from the implanted pulse generator to the patient based in part on the physiological concentration of an ion. Data regarding the physiological concentration of the ion can then be reported to a non-implanted device via a
5 telemetry link. Data regarding the physiological concentration of the ion can be combined with data regarding the patient's cardio-respiratory system to form a composite profile of the patient's cardiac condition. Data regarding the patient's cardio-respiratory system can include an EKG signal, respiration rate, accelerometer data, trans-thoracic impedance, lead impedance, cardiac volume,
10 blood pressure, weight, and cardiac necrosis signals.

Methods of providing cardiac arrhythmia therapy can also include optically monitoring a physiological concentration of an ion in a bodily fluid of the patient with an implanted chemical sensor, transmitting data regarding the physiological concentration of the ion to an implanted cardiac rhythm device,
15 and delivering pulses from the implanted cardiac rhythm device to the patient based in part of the physiological concentration of the ion.

Methods of Optimized Diagnostic Indication

It will be appreciated that the integration of an implanted chemical sensor
20 with the functionality of an implanted cardiac rhythm management (CRM) device enables combinations of data to be synthesized into diagnostic indicators with previously unrealized utility. As a specific example, the implanted chemical sensor can provide data regarding analyte concentrations while the CRM device functionality can provide cardiac data such as an EKG signal. As
25 described above, the two types of data offer mutually orthogonal but linked views of the physiologic state of the patient. These two types of data, or in some embodiments more than two types, can be combined to form a composite profile of a patient's condition or composite risk index.

The value of combining the chemical sensor data with the CRM device
30 data can be illustrated in multiple examples. One example is a method involving coordination of an electrolyte concentration signal with that of an EKG signal. A rapid or erratic heart rate is easily identified by the CRM device functionality.

This data is coupled with the information from the chemical sensor, such as potassium ion concentration. As described above, an erratic heart-rate in the presence of very high or very low potassium concentrations indicates a greater level of risk to the patient than either condition separately. Methods of the invention can include embodying this logic as an algorithm and creating a warning indicator that can provide a local alert through an integrated transducer, a proximal alert from a bedside or external device in communication with the system, or a medical alert provided to a central monitoring system.

Another example is a method involving coordination of an electrolyte concentration signal with that of a respiration rate signal. CRM device functionality can include observing and identifying high respiration rates. Clinically, respiration rates can be associated with the physiological concentration of sodium ions and can indicate fluid volume overload conditions for the patient. Further, CRM device functionality can include data from an accelerometer that can verify that exercise is not the respiration driver. The combination of a volume overload signal with a verified high resting respiration rate is indicative of an imminent cardio-respiratory system crisis. Methods of the invention can include embodying this logic as an algorithm and creating a warning indicator that can provide a local alert through an integrated transducer, a proximal alert from a bedside or external device in communication with the system, or a medical alert provided to a central monitoring system.

Yet another example is a method involving coordination of EKG signal vector values with concentrations of analytes indicating cardiac tissue necrosis. Specifically, CRM device functionality can include identifying the vector component values of the EKG waveform and then categorizing these into normal or abnormal vector pattern bins. The chemical sensor can be configured to identify concentrations of troponin, cardiac specific troponin, or any other analyte that indicates cardiomyocyte necrosis. The method can include combination of the EKG vector analysis and the cardiac necrosis analyte concentration signal as part of a formalized algorithm. This method can provide greater specificity for identifying a cardiac infarct than a method based on analyzing either signal in isolation. Methods of the invention can include

embodying this logic as an algorithm and creating a warning indicator that can provide a local alert through an integrated transducer, a proximal alert from a bedside or external device in communication with the system, or a medical alert provided to a central monitoring system.

- 5 While several examples of specific methods of combining data from an implanted chemical sensor with data provided by CRM device functionality have been provided, it will be appreciated that many other methods are possible based on combining data in a similar fashion. By way of example, other methods can include combining one or more of chemical sensor signals with the
- 10 EKG, trans-thoracic impedance, accelerometer indicated activity, accelerometer indicated posture, heart sounds, lead impedance, cardiac volume, and other signals obtained from the CRM device. In a particular embodiment, potassium ion concentration is combined with blood pressure data.

Methods of Providing Automated Feedback

Methods described herein can be adapted to provide automatic feedback (such as indications or recommendations) to a patient regarding behavioral or pharmaceutical interventions appropriate to the stabilization, improvement, or maintenance of health. By way of example, methods can include the detection of an excessive or inadequate potassium level which can be fed into an algorithm resulting in the delivery of a message to the patient regarding the condition without caregiver intervention. The algorithm can be constructed to provide patients with recommendations for dietary and/or activity modification within a range of analyte values wherein the medical risk remains modest or negligible. The method can allow patients to reverse physiological trends before they become more serious or require the intervention of medical professionals.

In some embodiments, the method can include providing recommendations to the patient so that the patient can modulate the dose of a therapeutic agent to a more appropriate level. The method can also include providing a medical professional with data so that the medical professional can modulate the dose of a therapeutic agent and/or change the therapeutic agent.

The method can include categorizing a patient's current condition as within the bounds of self-management or requiring the intervention of a medical professional. The boundaries of these categories can be predetermined, determined adaptively by monitoring the patient norms, or set by a medical professional as desired to yield the optimal patient benefit.

The methods illustrated in this disclosure are not intended to be exclusive of other methods within the scope of the present subject matter. Those of ordinary skill in the art will understand, upon reading and comprehending this disclosure, other methods within the scope of the present subject matter.

One of ordinary skill in the art will understand that the modules, circuitry, and methods shown and described herein with regard to various embodiments of the invention can be implemented using software, hardware, and combinations of software and hardware. As such, the illustrated and/or described modules and circuitry are intended to encompass software implementations, hardware implementations, and software and hardware

implementations.

It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. It should also be noted that the term "or" is
5 generally employed in its sense including "and/or" unless the content clearly dictates otherwise.

It should also be noted that, as used in this specification and the appended claims, the phrase "configured" describes a system, apparatus, or other structure that is constructed or configured to perform a particular task or adopt a
10 particular configuration. The phrase "configured" can be used interchangeably with other similar phrases such as "arranged", "arranged and configured", "constructed and arranged", "constructed", "manufactured and arranged", and the like.

All publications and patent applications in this specification are
15 indicative of the level of ordinary skill in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated by reference.

This application is intended to cover adaptations or variations of the
20 present subject matter. It is to be understood that the above description is intended to be illustrative, and not restrictive. The scope of the present subject matter should be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Aspects of the present invention may be better understood with reference
25 to the following examples. These examples are not intended as limiting the scope of the invention.

EXAMPLES

Example 1: Determination of Ion Concentration Within Pocket

30 The objective of this study was to evaluate the potential effects of the fibrous capsule surrounding an Implantable Cardiac Defibrillator (ICD) on sodium, potassium and glucose concentrations immediately surrounding the

device. Twelve canines were implanted with an ICD device and cared for in accordance with standard laboratory procedures. After a period of time (specified in Table 1 below), fluid was collected from inside the implant encapsulation tissue (or pocket) and compared with corresponding blood serum.

5 An amount of fluid sufficient for testing was drawn from eight of the twelve canines (insufficient amounts of fluid were collected from the other four). K^+ , Na^+ , Glucose, and pH and concentrations were measured using a Radiometer ABL 825 blood analyte monitor for samples from those eight canines. Serum samples were also drawn from the twelve animals and similarly analyzed with
 10 the Radiometer ABL 800 blood analyte monitor. The data is shown in Table 1 below and summarized in Table 2 below:

Table 1: Relative Concentrations

ID	Pocket Age (Days)	K^+ (%)	Na^+ (%)	Glu (%)	pH(T)c (%)
1	61	128.6	96.8	7.4	98.7
2	61	153.8	99.3	2.5	102.0
3	57	119.4	100.7	0.86	97.6
4	61	123.7	98.7	1.18	100.3
5	64	148.6	99.3	3.5	101.6
6	64	104.9	102.1	2.3	92.9
7**	74	127.0	98.6	29.8	98.0
8	55	114.3	100.7	1.05	97.7
Range	55-74	104.9 – 153.8	96.8 – 102.1	0.86 – 29.8	92.9 – 106.3

* Pocket level compared to serum level, expressed in %. <100% indicates that the level was lower in the pocket. >100% indicates that the level was higher in the pocket.

**Lead re-positioned at distal end one week after implant

Table 2: Concentration Ranges

Range:	K^+ (mmol/L)	Na^+ (mmol/L)	Glucose (mg/dL)	pH(T)c

Normal*	3.4-5.6	141-159	74-145	7.310-7.420
Blood Serum (n=12)	3.5-4.2	146-154	67-119	7.334-7.440
Pocket Fluid (n=8)	4.0-6.0	144-150	1-31	6.859-7.846

* Normal ranges provided by Marshfield Labs, Marshfield, Wisconsin

The data show that relative to the reference range, K^+ levels were normal in the blood serum and normal to slightly elevated (average ratio of $127\% \pm 16\%$) in the pocket fluid. The Na^+ levels were normal in the blood serum and the pocket fluid (average ratio $100\% \pm 2\%$). The glucose levels were normal in the blood serum and highly suppressed in the pocket fluid (average ratio $6\% \pm 10\%$). The pH levels were normal in the blood serum and varied below, within, and above the normal range in the pocket fluid. This example shows that physiological ions such as K^+ and Na^+ can be accurately measured from within an encapsulation pocket.

Example 2: Planar Ion Selective Optical Sensing Element

CUPROPHAN[®] cellulose sheets infiltrated with glycerol (Akzo Nobel Chemicals; Chicago, Ill.) are washed with deionized water (10 minutes) to remove the glycerol. Each sheet is stretched on a glass plate and dried at room temperature.

A. Overcoat

An overcoat solution is prepared by dissolving 4 g dextran (MW 2,000,000) in 200 mL deionized water at $50^\circ C$. Then, 2 g MARASPERSE DBOS-4[®] dispersing agent (Diashowa Chemicals, Inc.; Rothschild, Wis.) is added and the mixture is shaken. Thereafter, 4 g MONARCH-700[®] carbon black (Cabot Corp.; Waltham, Mass.) is added with sonication to produce a uniform aqueous dispersion of carbon-black. To the dispersion is added 4 g 50% (aq.) NaOH solution with mixing. Subsequently, 6 g of a 50% ethylene glycol diglycidylether (EGDGE) solution in deionized water is mixed in. The resulting overcoat solution is sprayed evenly onto the CUPROPHAN[®] membrane and allowed to dry.

B. Crosslinking

A solution of 3 g of 50% NaOH solution and 85 g DMSO in 350 mL deionized water is prepared. 450 g of a 50% aqueous EGDGE solution is added and mixed. This crosslinking solution is poured onto the CUPROPHAN[®] sheets and retained for 1 hr followed by rinsing with deionized water.

5

C. HDA (1,6-Hexanediamine) reaction

Crosslinked CUPROPHAN[®] membranes are immersed in a solution of 120 g 70% HDA in 2.0 L deionized water for 2 hrs, rinsed with deionized water to wash off excess HDA.

10

D. FCCC Coupling Reaction

A dye solution is prepared by dissolving 30 mg FCCC in 30 mL DMF. Subsequently, 0.8 mL of 1,3-diisopropylcarbodiimide (DIC) and 190 mg benzotriazole hydrate (HOBt) are added and stirred for 15 minutes, after which 0.4 mL N,N-diisopropylamine (DIEA) is added with stirring. HDA-functionalized CUPROPHAN[®] sheets are removed from the deionized water, towel dried and immersed in the dye bath for 24 hours, after which the pieces are removed and washed with DMF, then dilute aqueous HCL (pH 2-3.5).

20

E. Sensor-Pulse Generator Assembly

A dye-coupled CUPROPHAN[®] sheet is laminated to a thin (0.175 mm) polycarbonate sheet (Bayer AG; Leverkusen, Germany) using a 2-part polyurethane adhesive such as FLEXOBOND[®] 430 (Bacon Industries, Inc.; Irvine, Calif.). On the polycarbonate side, a CW14[™] pressure sensitive adhesive sheet (RSW Inc., Specialty Tape Div.; Racine, Wis.) is attached and the release-liner is removed. Discs are punched from the laminate using a hole-puncher and placed on an optical window of a pulse generator, configured with optoelectronics as described below for measuring potassium dependent emissions from the sensing element.

30

F. Optical Response of Potassium Sensor

GaN LEDs from Nichia Chemical Industries, Tokushima, Japan, or Toyoda Gosei Co., Ltd (under the brand name LEDTRONICS[™]) are disposed

within the pulse generator and configured to be amplitude modulated at a 30 kHz carrier frequency, with a burst duration of 0.2 seconds, a repetition rate of 5 seconds, and an average output power of 2.5 mW. The light is focused, passed through a bandpass excitation filter (e.g. 390 nm \pm 0.25 nm; %T=52%; out-of-band blocking =0.001%T; available from SpectroFilm; Woburn, Mass.), and transmitted to the sensing element through the optical window in the pulse generator. The modulated fluorescent return is similarly collected and passed through a bandpass emission filter (e.g. 475 \pm 0.35 nm; %T=64%; out-of-band blocking =0.001%T such as is available from SpectroFilm). The filtered optical signal is then be focused onto the active region of an S1337-33-BRTM photodiode detector (available from Hamamatsu Corp.; Bridgewater, N.J.) housed within the pulse generator. A small fraction of the excitation light is directly routed to the detector assembly and attenuated with a neutral density filter to provide a reference optical signal from the LED. In addition, an electronic switch is used to alternately sample the detector photo current and a 30 kHz electrical reference signal from the frequency generator. The detector output is directed to an electronic circuit within the pulse generator or satellite sensor that converts the photocurrent from the photodiode detector to a voltage. A transimpedance preamplification stage converts a photocurrent or the reference electrical signal to a voltage using an operational amplifier circuit. The following stage is a two-stage Delyiannis-Friend style bandpass filter designed to band limit the noise power while further amplifying the signal. The amplified photosignal or reference electrical signal is then digitally sampled at 100 kHz and processed to obtain a fluorescence intensity that is indicative of analyte concentration. Optionally, a pH sensor signal is also sampled and used to correct for minor pH dependent variations in the potassium sensor signal.

Example 3: Ion Selective Sensing Element in Hydrogel

30 A. Preparation of 1:1 Dimethylacrylamide:Vinyl Dimethylazlactone (DMA:VDM) Copolymer

A solution of 70 parts dimethylacrylamide (DMA) and 70 parts 2-vinyl-4,4- dimethyl-2-oxazoline-5-one (vinyl dimethylazlactone, VDM, commercially

available from SNPE, Princeton, N.J.) in 210 parts methylethyl ketone (MEK) is mixed with 0.7 parts N,N'- azobis(isobutyronitrile) initiator (AIBN, commercially available as VAZO[®] 64, Wako Chemicals USA, Inc., Richmond, Va.). The mixture is sparged with nitrogen for 5 minutes, then sealed in a jar and tumbled in at 60[°] C for 24 hours.

B. Lithographic Patterning of DMA:VDM Using 4-(p-Azidosalicyamido) Butylamine (ASBA)

10 Under low-lighting conditions, 25 mg of 4-(p-azidosalicyamido)butylamine (ASBA, commercially available from Pierce Chemical Co., Rockford, Ill.) and 10 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide promoter (EDC, HCl salt, Pierce Chemical Co., Rockford, Ill.) is dissolved in 0.5 ml of 95:5 (v/v) isopropanol:water. This
15 solution and one drop of aq. 1N HCl are added to 1 mL of a 40% (w/w) solution of 50:50 DMA:VDM copolymer (Example 1) in MEK. Thermal coupling of the butylamine portion of ASBA to azlactone functional groups is allowed to take place for 2 hour at room temperature. The MEK solution of the resulting mixture is spin-coated onto a PMMA substrate and dried in a vacuum desiccator for 15
20 minutes. The sample is lithographically exposed to UV irradiation at 10-30 mW/cm² measured at 365 nm through a photomask for 3 minutes to photocrosslink through the azido portion of bound ASBA. The mask is removed and the sample is washed thoroughly with pure isopropyl alcohol, leaving gel patterns that match those of the photomask. This dual cure approach increases
25 the efficiency for crosslinking compared to a bisazide crosslinker.

C: Preparation of amine-functional FCCC

The half-protected mono-N- *tert*-butyloxycarbonyl (t-BOC)-propylenediamine (Molecular Probes-Invitrogen) is useful for converting
30 organic solvent-soluble carboxylic acids into aliphatic amines. Following coupling of the half-protected aliphatic diamine to the activated carboxylic acid of FCCC under standard conditions, the *t*-BOC group is quantitatively removed

with trifluoroacetic acid. The resultant aliphatic amine derivative of FCCC is then reacted directly with azlactone functional polymer or hydrogel.

D: Preparation of FCCC functional hydrogel

5 To demonstrate the reactivity of the photo-crosslinked composition, a second sample of azlactone hydrogel is prepared and treated as follows: 50 nM of amine-functionalized FCCC is dissolved in 20 uL of carbonate bicarbonate buffer (0.05 M, pH 9.2). The indicator solution is spotted onto the photo-cured DMA:VDM coating using a needle. The sample is put in a sealed, humidified
10 container for 2 hours at room temperature before washing with DI water and incubating in DI water for 10 hours.

Example 4: Ion-Selective Optical Sensing Element in an Ion Permeable HEMA:PEGMA Hydrogel Film

15

A: Preparation of acrylamide functional FCCC

Amine-functional FCCC, prepared as described in Example 3 is reacted with the succinimidyl ester of 6-((acryloyl)amino)hexanoic acid (Molecular Probes-Invitrogen) under standard conditions to yield acrylamide functional
20 FCCC.

B: Fabrication of Polyhema Layer

A solution of 40 wt.% hydroxyethyl methacrylate (HEMA), 8.3 wt.% poly(ethyleneglycol)methacrylate (PEGMA, Mn ca 360), 1.5 wt.% acrylamide
25 functional FCCC, 50% deionized water and 0.2 wt.% Irgacure 651 is put into a mold consisting of two slide glasses, one having a hydrophobic octadecasilane treated surface, the other having a trimethoxysilylpropylmethacrylate treated surface and separated by a spacer with 16 um thickness. After polymerization by exposure to UV light for 10 min the hydrophobically treated glass slide is
30 removed, leaving a HEMA:PEGMA hydrogel film covalently attached to the remaining glass slide and comprising covalently incorporated FCCC fluoroionophore.

C: Optical Overcoat

Optionally, the optical overcoat as described in Example 2 is applied over the HEMA:PEGMA hydrogel film according to procedure of Example 2.

5

Example 5: Preparation of Sensing Elements using Plasticized PVC polymer

A: Preparation of Sensing Beads

Microscopic beads based on 30 wt. % of poly(vinyl chloride), PVC and
10 70 wt. % of bis(ethylhexyl)sebacate, BEHS are prepared using a spray dry method. A THF solution containing 1 wt. % PVC and 1 wt. % of BEHS is sprayed with a nebulizer under heated air stream from a heat gun and PVC/BEHS particles (2.5 ± 1 μm in diameter) are collected in a cyclone chamber.

15 50 mg of BEHS solution containing 0.5 mg of hydrogen ion selective chromoionophore III, 1.6 mg of NaHFPB and 22.3 mg of sodium ionophore, bis(12-crown-4) are added to 300 mg of the PVC/BEHS beads and thoroughly mixed, to form Na^+ /pH sensing microscopic beads.

20 50 mg of BEHS, 0.5 mg of hydrogen ion sensitive chromoionophore III, 1.6 mg of NaHFPB and 6.3 mg of potassium ionophore III (BME-44) are dissolved in 0.5 ml of 1,1-dichloromethane (DCM). The resulting solution is allowed to stand for 5 hours to evaporate the DCM. Into this cocktail, 300 mg of PVC/BEHS microscopic beads are added and then thoroughly mixed to form K^+ /pH sensing microscopic beads.

25 50 mg of BEHS solution is added to 300 mg of the PVC/BEHS beads and thoroughly mixed to form optical white reference beads.

B: Suspension of Beads in Hydrogel

For both sensing and optical reference beads, to prevent conglomerating
30 of the sensing beads, the beads are suspended and fixed in a hydrogel matrix. Two milligrams of the sensing or reference beads are well mixed with 1 mg of PEG and 1 mg of aqueous monomer solution containing 30 wt. % of acrylamide, 1 wt. % of N,N'-methylene-bis-acrylamide and 0.5 wt. % of photoinitiator,

Irgacure 2959. The suspension is placed in between two slide glasses and then photopolymerized upon UV light irradiation for 15 min.

C: Fabrication of a polyHEMA-based Sensor Body

5 HEMA (2-hydroxyethyl methacrylate) based sensor bodies are prepared by making a polymer plate using a photopolymerization method applied to the monomer solution in between two slide glasses separated by a spacer. To prevent strong adhesion of the resulting polymer to the glass surface, surface modified slide glasses with octadecylsilane are used. The slides (25 x 75 x 1
10 mm) are cleaned in a 1N HNO₃ solution at 70 °C for 2 hours and after cooling they were rinsed with milliQ water. After drying in an oven, cleaned slide glasses are placed into 1 L of toluene with 1.5 g of octadecyltrichlorosilane and heated under reflux for 6 hours. The thus surface modified slide glasses are washed by ethanol and milliQ water, and used as substrates for
15 photopolymerization.

A solution of 80 wt. % HEMA, 8.0 wt. % PEGMA (poly(ethylene glycol) methacrylate), 2.0 wt. % DEGDMA (di(ethylene glycol)dimethacrylate), 9.8 wt. % deionized water and 0.2 wt. % Irgacure 651 are transferred into a mold consisting of two surface modified slide glasses separated by a spacer with 400
20 um thickness. The solution is polymerized to form a crosslinked hydrogel by exposure to low intensity 365 nm UV light (ca 2mW/cm²) for 10 min. After polymerization, the thus prepared polyHEMA film is removed from the mold. To prepare wells in the polyHEMA film for each sensing capsule, an excimer laser is used with a mask made of a brass plate 200 um thick in which four holes
25 1 mm in diameter are linearly aligned with 1.3 mm distances in between holes to create sensor compartments in a single sensor body. After successful laser drilling, the polyHEMA film with wells is washed with deionized water.

D: Fabrication of sensor window membrane

30 To prepare the sensor window membrane, a solution of 32.9 wt. % HEMA, 16.9 wt. % PEGMA, 50 wt. % deionized water and 0.2 wt. % Irgacure 651 is put into a mold consisting of two slide glasses having hydrophobic

surfaces separated by a spacer with 16 μm thickness. After polymerization by exposure to UV light for 12 min, one of the slide glasses in the mold is carefully removed. In this case, the polyHEMA window membrane with 16 μm thickness remains on the surface of another slide glass.

5

E. Construction of sensor body with wells

To adhere the sensor body with the window membrane, 10 μL of the above mentioned monomer solution is applied to the surface of the thus prepared window membrane on the slide glass and spread. The sensor body is then placed
10 on the window membrane, covered with a slide glass and clamped with binder clips. By exposure to UV light for 15 min, the polyHEMA-based sensor body containing wells with sealed bottoms is successfully prepared.

F. Filling the sensor wells and completing construction of the sensor

15 The thus prepared sensor body is placed on a slide glass with sealed bottoms down and fixed with Scotch tape at the edges of the sensor body. In the respective sensor compartments Na^+ /pH sensing beads, K^+ /pH sensing beads and optical white beads for a sensor body with three wells are stuffed by using a tiny glass rod under a stereo microscope.

20 Another piece of window membrane on a slide glass with hydrophobic surface is then prepared by using the same method mentioned above. Ten μL of the monomer solution mentioned above is applied on the surface of the window membrane and then spread. After removing the tape, the sensor body stuffed with beads on the slide glass is covered with the thus prepared window
25 membrane together with the slide glass and cramped with binder clips. By exposure to UV light for 15 min, all wells with beads in the sensor body are sealed with another window membrane. At this point the sensors are ready for testing.

G. Optical response of K^+ sensor

30 Reflectance spectra of the optical K^+ sensor in Tris/HCl buffer at pH 7.4 are measured using an a fiber optic spectrometer (e.g. BIF400 UV-VIS, Ocean

Optics, CA). As potassium ion concentration increases over the range of 0 mM to 10 mM K^+ , reflectance at 505 nm (corresponding to the acidic form of chromoionophore III) decreases while the reflectance at 580 nm (corresponding to the basic form of chromoionophore III) increases. The white beads can be used as an optical reference for these measurements. Optionally, the ratio of the 505 and 580 nm reflectances can be used in calculating the potassium ion concentration.

Alternatively, optical characterization of the films can be done via fluorescence spectroscopy. When the film comes in contact with potassium ions, the release of protons from the film leads to a measurable change in its fluorescence properties. Emission peaks are observed at 647 nm and 683 nm. The former corresponds to the protonated form of chromoionophore III, while the latter corresponds to the deprotonated form. When the concentration of K^+ in the sample increases, the protonated peak at 647 nm decreases and the deprotonated peak at 683 nm increases. It has been reported that ratiometric analysis can minimize the effects of photobleaching and variations in lamp intensity. Therefore the intensity ratio of the two peaks (647 and 683 nm) is used instead of the absolute fluorescence.

20

H. Sensor Constructions

Precision coatable sensor constructions based on above described sensor beads are fabricated. The process includes (1) mixing acrylamide and bis-acrylamide monomers and polyethylene glycol oligomers with sensor beads or sensing dyes and a thermal or photo-chemical curing agent (2) coating the mixture onto a sensor backing (3) initiating cure to promote formation of a hydrogel and adhesion of the hydrogel to wells on the sensor backing (4) formation and adhesion of a HEMA window membrane to the resulting hydrogel compositions.

30 A multi-layer laminate sensor can be fabricated. The process includes (1) cellulose acetate membrane optionally impregnated with thermal or photo-cross linked HEMA polymers as the window membrane (2) a partitioned spacer

layer bonded to the dialysis membrane and comprising void spaces filled with the sensor bead (3) an optical window bonded to the partitioned spacer layer.

What is claimed is:

1. An implantable medical device comprising:
 - a pulse generator; and
 - a chemical sensor in communication with the pulse generator, the chemical sensor configured to detect an ion concentration in a bodily fluid, the chemical sensor comprising:
 - a sensing element;
 - an optical excitation assembly configured to illuminate the sensing element; and
 - an optical detection assembly configured to receive light from the sensing element.
2. The implantable medical device of claim 1, the sensing element comprising a polymeric matrix permeable to sodium ions, potassium ions, and hydronium ions.
3. The implantable medical device of claim 2, the polymeric matrix comprising a polymer selected from the group consisting of cellulose, polyvinyl alcohol, dextran, polyurethanes, quaternized polystyrenes, sulfonated polystyrenes, polyacrylamides, polyhydroxyalkyl acrylates, polyvinyl pyrrolidones, polyamides, polyesters, and mixtures and copolymers thereof.
4. The implantable medical device of claim 1, the sensing element having a first side and a second side, the first side opposite the second side, the optical excitation assembly and the optical detection assembly both disposed on the first side.
5. The implantable medical device of claim 4, further comprising an opaque cover layer disposed on the second side of the sensing element, the opaque cover layer comprising an ion permeable polymeric matrix.

6. The implantable medical device of claim 1, the chemical sensor comprising a communication interface configured to communicate wirelessly with the pulse generator.
7. The implantable medical device of claim 1, the chemical sensor comprising a communication interface configured to communicate with the pulse generator via a radio frequency link, an ultrasonic link, or an acoustic link.
8. The implantable medical device of claim 1, the chemical sensor electrically or optically coupled to the pulse generator.
9. The implantable medical device of claim 1, the chemical sensor configured to detect an ion selected from the group consisting of potassium, sodium, chloride, calcium, magnesium, lithium and hydronium.
10. The implantable medical device of claim 1, the sensing element comprising a complexing moiety and a fluorescing moiety, the fluorescing moiety exhibiting differential fluorescent intensity based upon binding of the complexing moiety to an ion.
11. The implantable medical device of claim 10, the complexing moiety selected from the group consisting of cryptands, crown ethers, bis-crown ethers, calixarenes, noncyclic amides, hemispherands, and ion selective antibiotics.
12. The implantable medical device of claim 1, the sensing element comprising a fluoroionophore selected from the group consisting of lithium specific fluoroionophores, sodium specific fluoroionophores, and potassium specific fluoroionophores.

13. The implantable medical device of claim 1, the sensing element configured to fluorescently emit light at two different wavelengths.
14. The implantable medical device of claim 1, the sensing element comprising a complexing moiety and a colorimetric moiety, the colorimetric moiety exhibiting differential light absorbance on binding of an ion to the complexing moiety.
15. The implantable medical device of claim 14, the complexing moiety selected from the group consisting of cryptands, crown ethers, bis-crown ethers, calixarenes, noncyclic amides, hemispherands, and ion selective antibiotics.
16. The implantable medical device of claim 1, the sensing element comprising an ionophore selected from the group consisting of sodium specific ionophores, potassium specific ionophores, calcium specific ionophores, magnesium specific ionophores, and lithium specific ionophores.
17. The implantable medical device of claim 1, the bodily fluid selected from the group consisting of blood, interstitial fluid, serum, lymph, and serous fluid.
18. The implantable medical device of claim 1, the excitation assembly comprising a light source, the light source comprising a light emitting diode.
19. The implantable medical device of claim 1, the excitation assembly comprising
a first light emitting diode; and
a second light emitting diode; the first and second light emitting diodes configured to emit light at different wavelengths.
20. The implantable medical device of claim 1, the detection assembly comprising a component selected from the group consisting of a photodiode, a charge-coupled device (CCD), a junction field effect transistor (JFET) optical sensor, and a

complementary metal-oxide semiconductor (CMOS) optical sensor.

21. The implantable medical device of claim 1, the pulse generator comprising:
 - a pulse generator circuit; and
 - an implantable housing configured to encapsulate the pulse generator circuit.
22. The implantable medical device of claim 21, the chemical sensor coupled to the implantable housing.
23. The implantable medical device of claim 21, the implantable housing defining an aperture occluded by a transparent member, the sensing element in optical communication with the excitation assembly and the detection assembly through the transparent member.
24. The implantable medical device of claim 21, further comprising:
 - a cardiac pacing lead; and
 - a device header coupled to the implantable housing, the device header configured to provide an electrical connection between the cardiac pacing lead and the pulse generator;
 - the chemical sensor coupled to the device header.
25. The implantable medical device of claim 1, further comprising:
 - a cardiac pacing lead, the chemical sensor coupled to the cardiac pacing lead.
26. The implantable medical device of claim 1, the implantable medical device comprising one of a pacemaker, a cardiac resynchronization therapy (CRT) device, a remodeling control therapy (RCT) device, a cardioverter/defibrillator, a pacemaker-cardioverter/defibrillator, and a hemodynamic monitor.

27. The implantable medical device of claim 1, the chemical sensor configured to detect a second physiological analyte selected from the group consisting of glucose, creatinine, lactate, urea, brain-neural peptide (BNP), nitric-oxide, and troponin.

28. The implantable medical device of claim 1, the chemical sensor configured to detect a concentration of potassium ions and a concentration of a physiological analyte indicative of renal function.

29. An implantable cardiac rhythm management system comprising:
a pulse generator; and
a chemical sensor in communication with the pulse generator, the chemical sensor configured to detect an analyte concentration in a bodily fluid, the chemical sensor comprising:
a sensing element;
an optical excitation assembly configured to illuminate the sensing element;
and
an optical detection assembly configured to receive light from the sensing element.

30. A method for providing cardiac arrhythmia therapy to a patient comprising:
optically measuring a physiological concentration of an ion in a bodily fluid of the patient with an implanted chemical sensor;
transmitting data regarding the physiological concentration of the ion to an implanted pulse generator; and
delivering therapy from the implanted pulse generator to the patient based in part on the physiological concentration of the ion.

31. The method of claim 30, further comprising optically sensing a physiological concentration of a non-ionic component of the bodily fluid.

32. The method of claim 30, wherein transmitting data regarding the physiological concentration of the ion to an implanted pulse generator comprises wirelessly transmitting data to the implanted pulse generator.

33. The method of claim 30, further comprising reporting the data regarding the physiological concentration of the ion to a non-implanted device via a telemetry link.

34. The method of claim 30, further comprising reporting the data regarding the physiological concentration of the ion to a medical professional via a telemetry link.

35. The method of claim 30, further comprising combining the data regarding the physiological concentration of the ion with data regarding the patient's cardio-respiratory system to form a composite profile of the patient's cardiac condition.

36. The method of claim 35, further comprising reporting the composite profile of the patient's cardiac health to a non-implanted device via a telemetry link.

37. The method of claim 35, the data regarding the patient's cardio-respiratory system selected from the group consisting of an EKG signal, respiration rate, accelerometer data, trans-thoracic impedance, lead impedance, cardiac volume, blood pressure, weight, and cardiac necrosis signals.

38. A method for monitoring diuretic therapy comprising:

 optically sensing a physiological concentration of an ion in a bodily fluid of a patient with an implanted chemical sensor;

 communicating data regarding the physiological concentration of the ion to an implanted pulse generator; and

 altering the delivery of the diuretic therapy to the patient based in part on the physiological concentration of the ion.

39. The method of claim 38, wherein optically sensing a physiological concentration of an ion in a bodily fluid of the patient comprises optically measuring potassium ion concentration.
40. The method of claim 39, further comprising optically measuring a concentration of a chemical indicative of renal function with the implanted chemical sensor.
41. The method of claim 40, further comprising reporting the physiological ion concentration and the concentration of the chemical indicative of renal function to a medical professional.
42. The method of claim 40, further comprising reporting the physiological ion concentration and the concentration of the chemical indicative of renal function to a non-implanted device via a telemetry link.
43. The method of claim 40, the chemical indicative of renal function comprising creatinine or urea.
44. The method of claim 38, further comprising determining whether the patient is suffering from hypokalemia or hyperkalemia.
45. The method of claim 38, the bodily fluid selected from the group consisting of blood, interstitial fluid, serum, lymph, and serous fluid.
46. A method for controlling delivery of an active agent into a human body, the method comprising:
measuring a physiological concentration of one or more analytes with an implanted system comprising a pulse generator and a chemical sensor, the chemical sensor comprising a sensing element, an excitation assembly, and a detection

assembly; and

varying delivery of the substance at least in part as a function of the measured concentration of the one or more analytes.

47. The method of claim 46, the one or more analytes comprising at least one ion selected from the group consisting of potassium, sodium, chloride, calcium, magnesium, lithium and hydronium.

48. The method of claim 46, the one or more analytes comprising an analyte indicative of renal function.

49. The method of claim 46, the one or more analytes comprising an analyte indicative of cardiac function.

50. The method of claim 46, the active agent comprising a diuretic.

51. The method of claim 46, in which measuring a physiological concentration comprises measuring a concentration in a bodily fluid selected from the group consisting of blood, interstitial fluid, serum, lymph, and serous fluid.

1/7




FIG. 1




FIG. 2

2/7




FIG. 3




FIG. 4

3/7




FIG. 5




FIG. 6

4/7




FIG. 7




FIG. 8

5/7




FIG. 9




FIG. 10




FIG. 11

7/7




FIG. 12

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/068954

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61N1/365

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 040 533 A (FEARNOT NEAL E [US]) 20 August 1991 (1991-08-20)	1,4,5,7, 8,12-15, 17, 20-24, 26-29
Y	column 4, line 33 - column 6, line 64; figure 1	2,3,6, 9-11,16, 18,19,25
A	WO 2006/017169 A (CARDIAC PACEMAKERS [US]; CHAVAN ABHI [US]; ROSS JEFFREY [US]; MORRISSE) 16 February 2006 (2006-02-16)	1
Y	paragraph [0020]; claims 11,12	2,3,6
	----- -/-- -----	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

23 October 2007

Date of mailing of the international search report

31/10/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

SOPELANA MARTINEZ, J

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2007/068954

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00/25863 A (MEDTRONIC INC [US]) 11 May 2000 (2000-05-11)	1
Y	page 11, line 16 - line 18; figure 1 page 21, line 19 - line 22 page 40, line 3 - line 6	18,19,25
A	WO 2004/081522 A (BECKMAN COULTER INC [US]; PEPER SHANE [US]; QIN YU [US]; BAKKER ERIC [] 23 September 2004 (2004-09-23)	1
Y	page 9, line 12 - line 14 page 24, line 9 page 41, line 8 - line 22 page 42, line 12 - line 14 page 47, line 23 page 48, line 6 - line 7	9-11,16

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2007/068954

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 30-51
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2007/068954

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
US 5040533	A	20-08-1991	NONE	
WO 2006017169	A	16-02-2006	EP 1784122 A2 US 2006008500 A1	16-05-2007 12-01-2006
WO 0025863	A	11-05-2000	US 6134459 A	17-10-2000
WO 2004081522	A	23-09-2004	NONE	